U.S. patent application number 15/799520 was filed with the patent office on 2018-08-02 for piperazine-substituted benzothiophenes for treatment of mental disorders.
This patent application is currently assigned to Otsuka Pharmaceutical Co., Ltd.. The applicant listed for this patent is Otsuka Pharmaceutical Co., Ltd.. Invention is credited to Nobuaki ITO, Hideaki KURODA, Jun MATSUBARA, Shin MIYAMURA, Kunio OSHIMA, Satoshi SHIMIZU, Haruka TAKAHASHI, Tatsuyoshi TANAKA, Hiroshi YAMASHITA.
Application Number | 20180214444 15/799520 |
Document ID | / |
Family ID | 36645750 |
Filed Date | 2018-08-02 |
United States Patent
Application |
20180214444 |
Kind Code |
A1 |
YAMASHITA; Hiroshi ; et
al. |
August 2, 2018 |
Piperazine-Substituted Benzothiophenes For Treatment of Mental
Disorders
Abstract
The present invention provides a heterocyclic compound
represented by the general formula (1): The compound of the present
invention has a wide treatment spectrum for mental disorders
including central nervous system disorders, no side effects and
high safety. ##STR00001##
Inventors: |
YAMASHITA; Hiroshi;
(Tokushima, JP) ; ITO; Nobuaki; (Tokushima,
JP) ; MIYAMURA; Shin; (Tokushima, JP) ;
OSHIMA; Kunio; (Tokushima, JP) ; MATSUBARA; Jun;
(Tokushima, JP) ; KURODA; Hideaki; (Tokushima,
JP) ; TAKAHASHI; Haruka; (Tokushima, JP) ;
SHIMIZU; Satoshi; (Tokushima, JP) ; TANAKA;
Tatsuyoshi; (Tokushima, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Otsuka Pharmaceutical Co., Ltd. |
Tokyo |
|
JP |
|
|
Assignee: |
Otsuka Pharmaceutical Co.,
Ltd.
Tokyo
JP
|
Family ID: |
36645750 |
Appl. No.: |
15/799520 |
Filed: |
October 31, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15697196 |
Sep 6, 2017 |
9839637 |
|
|
15799520 |
|
|
|
|
15585098 |
May 2, 2017 |
|
|
|
15697196 |
|
|
|
|
15267025 |
Sep 15, 2016 |
|
|
|
15585098 |
|
|
|
|
14928972 |
Oct 30, 2015 |
9480686 |
|
|
15267025 |
|
|
|
|
14089504 |
Nov 25, 2013 |
9206167 |
|
|
14928972 |
|
|
|
|
13688108 |
Nov 28, 2012 |
8618109 |
|
|
14089504 |
|
|
|
|
12970690 |
Dec 16, 2010 |
8349840 |
|
|
13688108 |
|
|
|
|
11659005 |
Dec 4, 2008 |
7888362 |
|
|
PCT/JP2006/308162 |
Apr 12, 2006 |
|
|
|
12970690 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 409/14 20130101;
A61P 25/18 20180101; A61P 25/24 20180101; C07D 405/12 20130101;
A61P 25/00 20180101; A61P 25/22 20180101; A61K 31/496 20130101;
A61P 25/16 20180101; A61P 25/32 20180101; A61P 25/14 20180101; C07D
409/12 20130101; A61P 25/28 20180101 |
International
Class: |
A61K 31/496 20060101
A61K031/496; C07D 409/14 20060101 C07D409/14; C07D 405/12 20060101
C07D405/12; C07D 409/12 20060101 C07D409/12 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 14, 2005 |
JP |
2005-116698 |
Claims
1. A heterocyclic compound represented by the formula (1):
##STR00178## [wherein ring Q represented by ##STR00179## represents
##STR00180## (wherein ##STR00181## represents --NH--CH.sub.2--,
--N.dbd.CH--, --CH.sub.2--NH-- or --CH.dbd.N--; and the
carbon-carbon bond between the 3-position and 4-position of the
heterocyclic skeleton containing Z and Y represents a single bond
or a double bond); the ring Q may have at least one substituent
selected from the group consisting of a lower alkyl group, a lower
alkenyl group, a lower alkynyl group, a hydroxy group, a lower
alkoxy group, a halogenated lower alkyl group, an aryl group, an
aryl lower alkyl group, an aryl lower alkoxy group, an arylcarbonyl
group, a lower alkenyloxy group, a lower alkanoyl group, a lower
alkanoyloxy group, a cycloalkyl group, a cycloalkyl lower alkyl
group, a halogen atom, a carbamoyl group which may have a lower
alkyl group, a carboxy group, a lower alkoxycarbonyl group, an
amino group which may have a lower alkanoyl group, a nitro group, a
hydroxy lower alkyl group, an amino lower alkyl group which may
have a lower alkyl group, a thienyl group, a saturated 3- to
8-membered heteromonocyclic group containing 1 to 2 nitrogen
atoms-substituted lower alkyl group and an oxo group; R.sub.2
represents a hydrogen atom or a lower alkyl group; and A represents
--O-A.sub.1- (wherein A.sub.1 represents an alkylene group which
may be substituted with a hydroxy group (wherein the alkylene group
may contain one oxygen atom) or a lower alkenylene group) or a
lower alkylene group; provided that when A represents a lower
alkylene group, the ring Q represents a bicyclic group selected
from the group consisting of: ##STR00182## (wherein the
carbon-carbon bond represents a single bond or a double bond)] or a
salt thereof.
2. The heterocyclic compound of the formula (1) according to claim
1, wherein the ring Q represents a bicyclic group selected from the
group consisting of: ##STR00183## (wherein the carbon-carbon bond
between the 3-position and 4-position of the bicyclic heterocyclic
skeleton represents a single bond or a double bond); the ring Q may
have 1 to 3 substituents selected from the group consisting of a
lower alkyl group, a lower alkenyl group, a lower alkynyl group, a
hydroxy group, a lower alkoxy group, a halogenated lower alkyl
group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower
alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy
group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl
group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a
cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl
group which may have a lower alkyl group, a carboxy group, a lower
alkoxycarbonyl group, an amino group which may have a lower
alkanoyl group, a nitro group, a hydroxy lower alkyl group, an
amino lower alkyl group which may have a lower alkyl group, a
thienyl group and a saturated 5- to 6-membered heteromonocyclic
group containing 1 to 2 nitrogen atoms-substituted lower alkyl
group; and A represents --O-A.sub.1- (wherein A.sub.1 represents a
C1-C6 alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom)), or a
salt thereof.
3. The heterocyclic compound of the formula (1) according to claim
2, wherein the ring Q represents a bicyclic group selected from the
group consisting of: ##STR00184## the ring Q may have 1 to 3
substituents selected from the group consisting of a lower alkyl
group, a lower alkenyl group, a lower alkynyl group, a hydroxy
group, a lower alkoxy group, a halogenated lower alkyl group, a
phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl
group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group,
a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group,
a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8
alkyl lower alkyl group, a halogen atom, a carbamoyl group which
may have a lower alkyl group, a carboxy group, a lower
alkoxycarbonyl group, an amino group which may have a lower
alkanoyl group, a nitro group, a hydroxy lower alkyl group, an
amino lower alkyl group which may have a lower alkyl group, a
phenyl group, a thienyl group and a pyrrolidinyl lower alkyl group;
and A represents --O-A.sub.1- (wherein A.sub.1 represents a C1-C6
alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom)), or a
salt thereof.
4. The heterocyclic compound of the formula (1) according to claim
2, wherein the ring Q represents a bicyclic group selected from the
group consisting of: ##STR00185## (the ring Q may have 1 to 3
substituents selected from the group consisting of a lower alkyl
group, a lower alkenyl group, a lower alkynyl group, a hydroxy
group, a lower alkoxy group, a halogenated lower alkyl group, a
phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl
group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group,
a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group,
a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8
alkyl lower alkyl group, a halogen atom, a carbamoyl group which
may have a lower alkyl group, a carboxy group, a lower
alkoxycarbonyl group, an amino group which may have a lower
alkanoyl group, a nitro group, a hydroxy lower alkyl group, an
amino lower alkyl group which may have a lower alkyl group, a
thienyl group and a pyrrolidinyl lower alkyl group) or a salt
thereof.
5. The heterocyclic compound of the formula (1) according to claim
1, wherein the ring Q represents a bicyclic group selected from the
group consisting of: ##STR00186## (wherein the carbon-carbon bond
between the 3-position and 4-position of the bicyclic heterocyclic
skeleton represents a single bond or a double bond); the ring Q may
have 1 to 3 substituents thereon selected from the group consisting
of a lower alkyl group, a lower alkenyl group, a lower alkynyl
group, a hydroxy group, a lower alkoxy group, a halogenated lower
alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl
lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower
alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower
alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl
group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a
carbamoyl group which may have a lower alkyl group, a carboxy
group, a lower alkoxycarbonyl group, an amino group which may have
a lower alkanoyl group, a nitro group, a hydroxy lower alkyl group,
an amino lower alkyl group which may have a lower alkyl group, a
thienyl group, a pyrrolidinyl lower alkyl group and an oxo group;
and A represents a lower alkylene group, or a salt thereof.
6. The heterocyclic compound of the formula (1) according to claim
5, wherein the ring Q represents a bicyclic group selected from the
group consisting of: ##STR00187## (wherein the carbon-carbon bond
between the 3-position and 4-position of the bicyclic heterocyclic
skeleton represents a single bond or a double bond); the ring Q may
have 1 to 3 substituents selected from the group consisting of a
lower alkyl group, a lower alkenyl group, a lower alkynyl group, a
hydroxy group, a lower alkoxy group, a halogenated lower alkyl
group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower
alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy
group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl
group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a
cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl
group which may have a lower alkyl group, a carboxy group, a lower
alkoxycarbonyl group, an amino group which may have a lower
alkanoyl group, a nitro group, a hydroxy lower alkyl group, an
amino lower alkyl group which may have a lower alkyl group, a
thienyl group and a pyrrolidinyl lower alkyl group, or a salt
thereof.
7. The heterocyclic compound of the formula (1) according to claim
3 selected from the group consisting of: (1)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one,
(2) 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
propoxy]-1H-quinolin-2-one, (3)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one, (4)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one, (5)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-3,4-dihydro-
-1H-quinolin-2-one and (6)
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one; or a salt thereof.
8. The heterocyclic compound of the formula (1) according to claim
4 selected from the group consisting of: (1)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one (2)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one, (3)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
butoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one, (4)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoqu-
inoline-1-one, (5)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e and (6) 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
propoxy]-2-methyl-2H-isoquinolin-1-one; or a salt thereof.
9. A pharmaceutical composition comprising a heterocyclic compound
of the formula (1) or a salt thereof according to any one of claims
1 to 8, as an active ingredient and a pharmaceutically acceptable
carrier.
10. The pharmaceutical composition according to claim 9 for
treating or preventing central nervous system disorders.
11. The pharmaceutical composition according to claim 10 for
treating or preventing central nervous system disorders selected
from the group consisting of schizophrenia; refractory, intractable
or chronic schizophrenia; emotional disturbance; psychotic
disorder; mood disorder; bipolar I type disorder; bipolar II type
disorder; depression; endogenous depression; major depression;
melancholy and refractory depression; dysthymic disorder;
cyclothymic disorder; panic attack; panic disorder; agoraphobia;
social phobia; obsessive-compulsive disorder; post-traumatic stress
disorder; generalized anxiety disorder; acute stress disorder;
hysteria; somatization disorder; conversion disorder; pain
disorder; hypochondriasis; factitious disorder; dissociative
disorder; sexual dysfunction; sexual desire disorder; sexual
arousal disorder; erectile dysfunction; anorexia nervosa; bulimia
nervosa; sleep disorder; adjustment disorder; alcohol abuse;
alcohol intoxication; drug addiction; stimulant intoxication;
narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic
or mental cause; anhedonia associated with depression; anhedonia
associated with schizophrenia; delirium; cognitive impairment;
cognitive impairment associated with Alzheimer's disease,
Parkinson's disease and other neurodegenerative diseases; cognitive
impairment caused by Alzheimer's disease; Parkinson's disease and
associated neurodegenerative diseases; cognitive impairment of
schizophrenia; cognitive impairment caused by refractory,
intractable or chronic schizophrenia; vomiting; motion sickness;
obesity; migraine; pain (ache); mental retardation; autism disorder
(autism); Tourette's disorder; tic disorder;
attention-deficit/hyperactivity disorder; conduct disorder; and
Down's syndrome.
12. A process for producing a pharmaceutical composition comprising
mixing a heterocyclic compound of the formula (1) or a salt thereof
according to any one of claims 1 to 8 with a pharmaceutically
acceptable carrier.
13. Use of a heterocyclic compound of the formula (1) or a salt
thereof according to any one of claims 1 to 8 as a drug.
14. Use of a heterocyclic compound of the formula (1) or a salt
thereof according to any one of claims 1 to 8 as a dopamine D.sub.2
receptor partial agonist and/or a serotonin 5-HT.sub.2A receptor
antagonist and/or an adrenaline .alpha..sub.1 receptor antagonist
and/or a serotonin uptake inhibitor and/or a serotonin reuptake
inhibitor.
15. A method for treating or preventing a central nervous system
disorder comprising administering a heterocyclic compound of the
formula (1) or a salt thereof according to any one of claims 1 to 8
to human or animal.
16. A process for producing a heterocyclic compound represented by
the formula (1): ##STR00188## [wherein ring Q represented by
##STR00189## represents ##STR00190## (wherein ##STR00191##
represents --NH--CH.sub.2--, --N.dbd.CH--, --CH.sub.2--NH-- or
--CH.dbd.N--; and the carbon-carbon bond between the 3-position and
4-position of the heterocyclic skeleton containing Z and Y
represents a single bond or a double bond); the ring Q may have at
least one substituent selected from the group consisting of a lower
alkyl group, a lower alkenyl group, a lower alkynyl group, a
hydroxy group, a lower alkoxy group, a halogenated lower alkyl
group, an aryl group, an aryl lower alkyl group, an aryl lower
alkoxy group, an arylcarbonyl group, a lower alkenyloxy group, a
lower alkanoyl group, a lower alkanoyloxy group, a cycloalkyl
group, a cycloalkyl lower alkyl group, a halogen atom, a carbamoyl
group which may have a lower alkyl group, a carboxy group, a lower
alkoxycarbonyl group, an amino group which may have a lower
alkanoyl group, a nitro group, a hydroxy lower alkyl group, an
amino lower alkyl group which may have a lower alkyl group, a
thienyl group, a saturated 3- to 8-membered heteromonocyclic group
containing 1 to 2 nitrogen atoms-substituted lower alkyl group and
an oxo group; R.sub.2 represents a hydrogen atom or a lower alkyl
group; and A represents --O-A.sub.1- (wherein A.sub.1 represents an
alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom) or a lower
alkenylene group) or a lower alkylene group; provided that when A
represents a lower alkylene group, the ring Q represents a bicyclic
group selected from the group consisting of: ##STR00192## (wherein
the carbon-carbon bond represents a single bond or a double bond)]
or a salt thereof, characterized by comprising a reaction of a
compound represented by the formula: ##STR00193## (wherein the ring
Q and A are the same as defined above, and X.sub.1 represents a
halogen atom or a group which causes a substitution reaction the
same as in a halogen atom) or a salt thereof with a compound
represented by the formula: ##STR00194## (wherein R.sub.2 is the
same as defined above) or a salt thereof.
Description
TECHNICAL FIELD
[0001] The present invention relates to a novel heterocyclic
compound.
BACKGROUND ART
[0002] Since causal factor of schizophrenia as well as of bipolar
disorder, mood disorders and emotional disorders is heterogeneous,
it is desirable that a drug has multiple pharmacological effects so
as to develop wide treatment spectrum.
[0003] WO2004/026864A1 discloses that a carbostyril derivative
represented by the general formula:
##STR00002##
(wherein A' represents --(CH.sub.2).sub.mCH.sub.2--,
--(CH.sub.2).sub.mO--, etc.; m represents an integer of 1 to 4; and
R.sup.A represents a hydrogen atom, a C.sub.1-4 alkyl group which
may be substituted with 1 to 3 fluorine atoms, etc.) has D.sub.2
receptor antagonist activity and serotonin 2A (5-HT.sub.2A)
receptor antagonist activity and it is effective for treatment of
schizophrenia and other central nervous system disorders).
[0004] However, there is no description in WO2004/026864A1 that
carbostyril derivatives described in the document have D.sub.2
receptor partial agonist activity, 5-HT.sub.2A receptor antagonist
activity, a receptor antagonist activity and serotonin uptake
inhibitory activity together and have a wide treatment
spectrum.
[0005] WO 2005/019215 A1 discloses the compounds represented by the
following formula:
##STR00003##
(wherein A is --(CH.sub.2).sub.mCH.sub.2--, --(CH.sub.2).sub.mO--
or the like; m is an integer of 2 to 5; D is N, C or the like; Z
and Q are independently N, C or CH, provided that at least one of Z
and Q is N; X and Y are independently C, N or the like, and the
bond between X and Y is a single or double bond; R.sup.1 is
hydrogen, (C.sub.1-C.sub.3)alkyl group or the like; R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 each represents hydrogen, alkyl group
or the like; and G represents a group of monocyclic or bicyclic
compound), which bind to dopamine D.sub.2 receptors. WO 2005/019215
A1 teaches that some compounds disclosed therein have an activity
as partial agonists of D.sub.2 receptors or an activity as
antagonists of D.sub.2 receptors, and may be effective for the
treatment of schizophrenia and other central nervous system.
[0006] However, WO 2005/019215 A1 does not specifically disclose
the compounds of the present invention.
DISCLOSURE OF THE INVENTION
[0007] An object of the present invention is to provide an
antipsychotic drug which has a wider treatment spectrum, less side
effects and excellent tolerability and safety as compared with
well-known typical and atypical antipsychotic drugs.
[0008] The present inventors have conducted intensive studies on
the above-described problem and consequently succeeded in
synthesizing a novel compound which has dopamine D.sub.2 receptor
partial agonist activity (D.sub.2 receptor partial agonist
activity), serotonin 5-HT.sub.2A receptor antagonist activity
(5-HT.sub.2A receptor antagonist activity) and adrenalin
.alpha..sub.1 receptor antagonist activity (.alpha..sub.1 receptor
antagonist activity) and further has serotonin uptake inhibitory
effect (or serotonin reuptake inhibitory effect) together in
addition to these effects. The present invention has been completed
based on this finding.
[0009] The present invention provides a heterocyclic compound
represented by the general formula (1):
##STR00004##
[wherein ring Q represented by
##STR00005##
represents
##STR00006##
(wherein
##STR00007## [0010] represents --NH--CH.sub.2--, --N.dbd.CH--,
--CH.sub.2--NH-- or --CH.dbd.N--; and the carbon-carbon bond [0011]
between the 3-position and 4-position of the heterocyclic skeleton
containing Z and Y represents a single bond or a double bond);
[0012] the ring Q may have at least one substituent selected from
the group consisting of a lower alkyl group, a lower alkenyl group,
a lower alkynyl group, a hydroxy group, a lower alkoxy group, a
halogenated lower alkyl group, an aryl group, an aryl lower alkyl
group, an aryl lower alkoxy group, an arylcarbonyl group, a lower
alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy
group, a cycloalkyl group, a cycloalkyl lower alkyl group, a
halogen atom, a carbamoyl group which may have a lower alkyl group,
a carboxy group, a lower alkoxycarbonyl group, an amino group which
may have a lower alkanoyl group, a nitro group, a hydroxy lower
alkyl group, an amino lower alkyl group which may have a lower
alkyl group, a thienyl group, a saturated 3- to 8-membered
heteromonocyclic group containing 1 to 2 nitrogen atoms-substituted
lower alkyl group and an oxo group;
[0013] R.sub.2 represents a hydrogen atom or a lower alkyl group;
and
[0014] A represents --O-A.sub.1- (wherein A.sub.1 represents an
alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom) or a lower
alkenylene group) or a lower alkylene group;
[0015] provided that when A represents a lower alkylene group, the
ring Q represents a bicyclic group selected from the group
consisting of:
##STR00008##
(wherein the carbon-carbon bond [0016] represents a single bond or
a double bond)] or a salt thereof.
[0017] The present invention provides a heterocyclic compound
represented by the general formula (1), wherein the ring Q
represents a bicyclic group selected from the group consisting
of:
##STR00009##
(wherein the carbon-carbon bond [0018] between the 3-position and
4-position of the bicyclic heterocyclic skeleton represents a
single bond or a double bond);
[0019] the ring Q may have 1 to 3 substituents selected from the
group consisting of a lower alkyl group, a lower alkenyl group, a
lower alkynyl group, a hydroxy group, a lower alkoxy group, a
halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl
group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a
naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy
group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo
C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen
atom, a carbamoyl group which may have a lower alkyl group, a
carboxy group, a lower alkoxycarbonyl group, an amino group which
may have lower alkanoyl group, a nitro group, a hydroxy lower alkyl
group, an amino lower alkyl group which may have a lower alkyl
group, a thienyl group and a saturated 5- to 6-membered
heteromonocyclic group containing 1 to 2 nitrogen atoms-substituted
lower alkyl group; and
[0020] A represents --O-A.sub.1- (wherein A.sub.1 represents a
C1-C6 alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom)), or a
salt thereof.
[0021] The present invention provides a heterocyclic compound
represented by the general formula (1), wherein the ring Q
represents a bicyclic group selected from the group consisting
of:
##STR00010##
the ring Q may have 1 to 3 substituents selected from the group
consisting of a lower alkyl group, a lower alkenyl group, a lower
alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated
lower alkyl group, a phenyl group, a phenyl lower alkyl group, a
naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl
lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a
lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8
alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom,
a carbamoyl group which may have a lower alkyl group, a carboxy
group, a lower alkoxycarbonyl group, an amino group which may have
a lower alkanoyl group, a nitro group, a hydroxy lower alkyl group,
an amino lower alkyl group which may have a lower alkyl group, a
phenyl group, a thienyl group and a pyrrolidinyl lower alkyl group;
and
[0022] A represents --O-A.sub.1- (wherein A.sub.1 represents a
C1-C6 alkylene group which may be substituted with a hydroxy group
(wherein the alkylene group may contain one oxygen atom)), or a
salt thereof.
[0023] The present invention provides a heterocyclic compound
represented by the general formula (1), wherein the ring Q
represents a bicyclic group selected from the group consisting
of:
##STR00011##
[0024] (the ring Q may have 1 to 3 substituents selected from the
group consisting of a lower alkyl group, a lower alkenyl group, a
lower alkynyl group, a hydroxy group, a lower alkoxy group, a
halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl
group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a
naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy
group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo
C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen
atom, a carbamoyl group which may have a lower alkyl group, a
carboxy group, a lower alkoxycarbonyl group, an amino group which
may have a lower alkanoyl group, a nitro group, a hydroxy lower
alkyl group, an amino lower alkyl group which may have a lower
alkyl group, a thienyl group and a pyrrolidinyl lower alkyl group)
or a salt thereof.
[0025] The present invention provides a heterocyclic compound
represented by the general formula (1), wherein the ring Q
represents a bicyclic group selected from the group consisting
of:
##STR00012##
(wherein the carbon-carbon bond [0026] between the 3-position and
4-position of the above-mentioned bicyclic heterocyclic skeleton
represents a single bond or a double bond);
[0027] the ring Q may have 1 to 3 substituents thereon selected
from the group consisting of a lower alkyl group, a lower alkenyl
group, a lower alkynyl group, a hydroxy group, a lower alkoxy
group, a halogenated lower alkyl group, a phenyl group, a phenyl
lower alkyl group, a naphthyl lower alkyl group, a phenyl lower
alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a
lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy
group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl
group, a halogen atom, a carbamoyl group which may have a lower
alkyl group, a carboxy group, a lower alkoxycarbonyl group, an
amino group which may have a lower alkanoyl group, a nitro group, a
hydroxy lower alkyl group, an amino lower alkyl group which may
have a lower alkyl group, a thienyl group, a pyrrolidinyl lower
alkyl group and an oxo group; and
[0028] A represents a lower alkylene group, or a salt thereof.
[0029] The present invention provides a heterocyclic compound
represented by the general formula (1), wherein the ring Q
represents a bicyclic group selected from the group consisting
of:
##STR00013##
(wherein the carbon-carbon bond [0030] between the 3-position and
4-position of the above-mentioned bicyclic heterocyclic skeleton
represents a single bond or a double bond);
[0031] the ring Q may have 1 to 3 substituents selected from the
group consisting of a lower alkyl group, a lower alkenyl group, a
lower alkynyl group, a hydroxy group, a lower alkoxy group, a
halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl
group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a
naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy
group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo
C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen
atom, a carbamoyl group which may have a lower alkyl group, a
carboxy group, a lower alkoxycarbonyl group, an amino group which
may have a lower alkanoyl group, a nitro group, a hydroxy lower
alkyl group, an amino lower alkyl group which may have a lower
alkyl group, a thienyl group and a pyrrolidinyl lower alkyl group,
or a salt thereof.
[0032] Among the heterocyclic compounds or salts thereof
represented by the formula (I), preferable compounds include a
compound or a salt thereof selected from: [0033] (1)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one,
[0034] (2)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-quinolin-2-one,
[0035] (3)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one, [0036] (4)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one, [0037] (5)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-3,4-dihydro-
-1H-quinolin-2-one and [0038] (6)
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one; or a salt thereof.
[0039] In addition, among the heterocyclic compounds or salts
thereof represented by the formula (1), preferable compounds
include a compound or a salt thereof selected from: [0040] (1)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one [0041] (2)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one, [0042] (3)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-2-methyl-3,4-dihydro-
-2H-isoquinolin-1-one, [0043] (4)
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoqu-
inolin-1-one, [0044] (5)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
propoxy]-2H-isoquinolin-1-one and [0045] (6)
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one; or a salt thereof.
[0046] The present invention provides a pharmaceutical composition
comprising a heterocyclic compound represented by the formula (1)
or a salt thereof as an active ingredient mixed with a
pharmaceutically acceptable carrier. The pharmaceutical composition
according to the present invention can be effectively used for the
treatment or prevention of central nervous system disorders.
[0047] The pharmaceutical composition according to the present
invention can be used as a pharmaceutical composition for treating
or preventing central nervous system disorders selected from the
group consisting of schizophrenia; refractory, intractable or
chronic schizophrenia; emotional disturbance; psychotic disorder;
mood disorder; bipolar I type disorder; bipolar II type disorder;
depression; endogenous depression; major depression; melancholy and
refractory depression; dysthymic disorder; cyclothymic disorder;
panic attack; panic disorder; agoraphobia; social phobia;
obsessive-compulsive disorder; post-traumatic stress disorder;
generalized anxiety disorder; acute stress disorder; hysteria;
somatization disorder; conversion disorder; pain disorder;
hypochondriasis; factitious disorder; dissociative disorder; sexual
dysfunction; sexual desire disorder; sexual arousal disorder;
erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep
disorder; adjustment disorder; alcohol abuse; alcohol intoxication;
drug addiction; stimulant intoxication; narcotism; anhedonia;
iatrogenic anhedonia; anhedonia of a psychic or mental cause;
anhedonia associated with depression; anhedonia associated with
schizophrenia; delirium; cognitive impairment; cognitive impairment
associated with Alzheimer's disease, Parkinson's disease and other
neurodegenerative diseases; cognitive impairment caused by
Alzheimer's disease, Parkinson's disease and associated
neurodegenerative diseases; cognitive impairment of schizophrenia;
cognitive impairment caused by refractory, intractable or chronic
schizophrenia; vomiting; motion sickness; obesity; migraine;
pain(ache); mental retardation; autism disorder (autism);
Tourette's disorder; tic disorder; attention-deficit/hyperactivity
disorder; conduct disorder; and Down's syndrome.
[0048] The present invention provides a process for producing a
pharmaceutical composition comprising mixing a heterocyclic
compound represented by the above-described formula (1) or a salt
thereof with a pharmaceutically acceptable carrier.
[0049] The present invention provides use of a heterocyclic
compound represented by the above-described formula (1) or a salt
thereof as a drug. Specifically provided is of a heterocyclic
compound represented by the above-described formula (1) or a salt
thereof, as a dopamine D.sub.2 receptor partial agonist and/or a
serotonin 5-HT.sub.2A receptor antagonist and/or an adrenaline
.alpha..sub.1 receptor antagonist and/or a serotonin uptake
inhibitor (or a serotonin reuptake inhibitor).
[0050] The present invention provides a method for treating or
preventing a central nervous system disorder comprising
administering a compound represented by the above-described formula
(1) or a salt thereof to human or animal.
[0051] The present invention provides a process for producing a
heterocyclic compound represented by the above-described formula
(1):
##STR00014##
or a salt thereof, characterized by comprising a reaction of a
compound represented by the formula:
##STR00015##
(wherein the ring Q and A are the same as defined above, and
X.sub.1 represents a halogen atom or a group which causes a
substitution reaction the same as in a halogen atom) or a salt
thereof with a compound represented by the formula:
##STR00016##
(wherein R.sub.2 is the same as defined above) or a salt
thereof.
[0052] Specifically, respective groups shown in the above general
formula (1) are as follows.
[0053] As a lower alkyl group, a linear or branched alkyl group
having 1 to 6 carbon atoms can be mentioned. More specifically,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
sec-butyl, n-pentyl, 1-ethylpropyl, isopentyl, neopentyl, n-hexyl,
1,2,2-trimethylpropyl, 3,3-dimethylbutyl, 2-ethylbutyl, isohexyl,
3-methylpentyl groups are included.
[0054] As a lower alkoxy group, a linear or branched alkoxy group
having 1 to 6 carbon atoms can be mentioned. More specifically,
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy,
tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy,
n-hexyloxy, isohexyloxy, 3-methylpentyloxy groups are included.
[0055] As a lower alkenyl group, a linear or branched alkenyl group
having 1 to 3 double bonds and 2 to 6 carbon atoms can be mentioned
including the both of trans and cis configurations. More
specifically, vinyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl,
2-methyl-1-propenyl, 2-methyl-2-propenyl, 2-propenyl, 2-butenyl,
1-butenyl, 3-butenyl, 2-pentenyl, 1-pentenyl, 3-pentenyl,
4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 2-penten-4-yl,
2-hexenyl, 1-hexenyl, 5-hexenyl, 3-hexenyl, 4-hexenyl,
3,3-dimethyl-1-propenyl, 2-ethyl-1-propenyl, 1,3,5-hexatrienyl,
1,3-hexadienyl, 1,4-hexadienyl groups are included.
[0056] As a lower alkynyl group, a linear or branched alkynyl group
having 2 to 6 carbon atoms can be mentioned. More specifically,
ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl,
2-pentynyl, 2-hexynyl groups are included.
[0057] As a halogen atom, fluorine atom, chlorine atom, bromine
atom and iodine atom can be mentioned.
[0058] As a halogenated lower alkyl group, a lower alkyl group as
illustrated above substituted with 1 to 7 halogen atoms, preferably
1 to 3 halogen atoms can be mentioned. More specifically,
fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl,
dichlorofluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,
pentafluoroethyl, 2-fluoroethyl, 2-chloroethyl,
3,3,3-trifluoropropyl, heptafluoropropyl,
2,2,3,3,3-pentafluoropropyl, heptafluoroisopropyl, 3-chloropropyl,
2-chloropropyl, 3-bromopropyl, 4,4,4-trifluorobutyl,
4,4,4,3,3-pentafluorobutyl, 4-chlorobutyl, 4-bromobutyl,
2-chlorobutyl, 5,5,5-trifluoropentyl, 5-chloropentyl,
6,6,6-trifluorohexyl, 6-chlorohexyl, perfluorohexyl are
included.
[0059] As an aryl group, for example, phenyl, biphenyl, naphthyl
groups can be mentioned and as a substituent on the phenyl ring or
naphthalene ring, a lower alkyl group (preferably linear or
branched alkyl group having 1 to 6 carbon atoms) as illustrated
above, lower alkoxy group (preferably linear or branched alkoxy
group having 1 to 6 carbon atoms) as illustrated above, and phenyl,
biphenyl, or naphthyl groups which may have 1 to 3 groups selected
from a nitro group and a halogen atom are included.
[0060] Specific examples of an aryl group include phenyl, 2- (or 3-
or 4-)methylphenyl, 2- (or 3- or 4-)nitrophenyl, 2- (or 3- or
4-)methoxyphenyl, 2- (or 3- or 4-)chlorophenyl, biphenyl,
.alpha.-naphthyl, .beta.-naphthyl groups.
[0061] As an aryl lower alkyl group, a lower alkyl group
(preferably linear or branched alkyl group having 1 to 6 carbon
atoms) as illustrated above which has 1 to 3, preferably one aryl
group as illustrated above can be mentioned.
[0062] Specific examples of an aryl lower alkyl group include
benzyl, 2- (or 3- or 4-)methylbenzyl, 2-(or 3- or 4-) nitrobenzyl,
2- (or 3- or 4-)methoxybenzyl, 2- (or 3- or 4-) chlorobenzyl, 1-
(or 2-)phenylethyl, 1-methyl-1-phenylethyl,
1,1-dimethyl-2-phenylethyl, 1,1-dimethyl-3-phenylpropyl,
.alpha.-naphthylmethyl, .beta.-naphthylmethyl groups.
[0063] As an aryl lower alkoxy group, a lower alkoxy group
(preferably linear or branched alkoxy group having 1 to 6 carbon
atoms) as illustrated above which has 1 to 3, preferably one aryl
group as illustrated above can be mentioned. Specific examples of
an aryl lower alkoxy group include benzyloxy, 2- (or 3- or
4-)methylbenzyloxy, 2- (or 3- or 4-) nitrobenzyloxy, 2-(or 3- or
4-)methoxy benzyloxy, 2- (or 3- or 4-)chlorobenzyl, 1- (or
2-)phenylethoxy, 1-methyl-1-phenyl ethoxy, 1,1-dimethyl-2-phenyl
ethoxy, 1,1-dimethyl-3-phenyl propoxy, .alpha.-naphthylmethoxy,
.beta.-naphthylmethoxy groups.
[0064] As an aryl moiety of an arylcarbonyl group, an aryl group as
illustrated above can be mentioned.
[0065] Specific examples of an arylcarbonyl group include benzoyl,
2- (or 3- or 4-)methylbenzoyl, 2- (or 3- or 4-)nitrobenzoyl, 2- (or
3- or 4-)methoxybenzoyl, 2- (or 3- or 4-)chlorobenzoyl,
.alpha.-naphthoyl, .beta.-naphthoyl groups.
[0066] As a lower alkenyloxy group, a lower alkenyloxy group having
a lower alkenyl group (preferably a linear or branched alkenyloxy
group having 1 to 3 double bonds and 2 to 6 carbon atoms) as
illustrated above can be mentioned. More specifically included are
vinyloxy, 1-propenyloxy, 1-methyl-1-propenyloxy,
2-methyl-1-propenyloxy, 2-propenyloxy, 2-butenyloxy, 1-butenyloxy,
3-butenyloxy, 2-pentenyloxy, 1-pentenyloxy, 3-pentenyloxy,
4-pentenyloxy, 1,3-butadienyloxy, 1,3-pentadienyloxy,
2-penten-4-yloxy, 2-hexenyloxy, 1-hexenyloxy, 5-hexenyloxy,
3-hexenyloxy, 4-hexenyloxy, 3,3-dimethyl-1-propenyloxy,
2-ethyl-1-propenyloxy, 1,3,5-hexatrienyloxy, 1,3-hexadienyloxy,
1,4-hexadienyloxy groups.
[0067] As a lower alkanoyl group, a linear or branched alkanoyl
group having 1 to 6 carbon atoms can be mentioned. More
specifically, formyl, acetyl, propionyl, butyryl, isobutyryl,
pentanoyl, tert-butylcarbonyl, hexanoyl groups are included.
[0068] As a lower alkanoyloxy group, a linear or branched
alkanoyloxy group having 1 to 6 carbon atoms can be mentioned. More
specifically, formyloxy, acetyloxy, propionyloxy, butyryloxy,
isobutyryloxy, pentanoyloxy, tert-butylcarbonyloxy, hexanoyloxy
groups are included.
[0069] As a cycloalkyl group, a cyclo C3-C8 alkyl group having 3 to
8 carbon atoms can be mentioned. Examples thereof include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl groups.
[0070] As a cycloalkyl lower alkyl group, a lower alkyl group as
illustrated above which has 1 to 3, preferably one cycloalkyl group
(preferably, cyclo C3-C8 alkyl group having 3 to 8 carbon atoms) as
illustrated above can be mentioned. More specifically included are
cyclopropylmethyl, cyclohexylmethyl, 2-cyclopropylethyl,
1-cyclobutylethyl, cyclopentylmethyl, 3-cyclopentylpropyl,
4-cyclohexylbutyl, 5-cycloheptylpentyl, 6-cyclooctylhexyl,
1,1-dimethyl-2-cyclohexylethyl, 2-methyl-3-cyclopropylpropyl
groups.
[0071] As a carbamoyl group which may have a lower alkyl group, a
carbamoyl group which may have 1 to 2 lower alkyl group
(preferably, alkyl group having 1 to 6 carbon atoms) as illustrated
above can be mentioned. More specifically included are carbamoyl,
N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-methyl-N-ethylcarbamoyl
groups.
[0072] As a lower alkoxycarbonyl group, those having a lower alkoxy
moiety as illustrated above, preferably a linear or branched
alkoxycarbonyl group having 1 to 6 carbon atoms can be mentioned.
More specifically included are methoxycarbonyl, ethoxycarbonyl,
n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl,
isobutoxycarbonyl, tert-butoxycarbonyl, sec-butoxycarbonyl,
n-pentyloxycarbonyl, neopentyloxy, n-hexyloxy carbonyl,
isohexyloxycarbonyl, 3-methylpentyloxycarbonyl groups.
[0073] As an amino group which may have a lower alkanoyl group,
those having one lower alkanoyl group as illustrated above
(preferably a linear or branched alkanoyl group having 1 to 6
carbon atoms) can be mentioned. More specifically, examples include
amino, N-formylamino, N-acetylamino groups.
[0074] As a hydroxy lower alkyl group, a lower alkyl group
(preferably, a linear or branched alkyl group having 1 to 6 carbon
atoms) as illustrated above having 1 to 5, preferably 1 to 3
hydroxy groups can be mentioned. More specifically included are
hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl,
2,3-dihydroxypropyl, 4-hydroxybutyl, 3,4-dihydroxybutyl,
1,1-dimethyl-2-hydroxyethyl, 5-hydroxypentyl, 6-hydroxyhexyl,
3,3-dimethyl-3-hydroxypropyl, 2-methyl-3-hydroxypropyl,
2,3,4-trihydroxybutyl, perhydroxyhexyl groups.
[0075] As an amino lower alkyl group which may have a lower alkyl
group, a lower alkyl group (preferably, a linear or branched alkyl
group having 1 to 6 carbon atoms) as illustrated above having 1 to
5, preferably one amino group which may have 1 to 2 lower alkyl
group (preferably, a linear or branched alkyl group having 1 to 6
carbon atoms) as illustrated above can be mentioned. More
specifically, examples of such an amino lower alkyl group which may
have a lower alkyl group include aminomethyl, 2-aminoethyl,
1-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl,
6-aminohexyl, 1,1-dimethyl-2-methyl-3-aminopropyl,
N,N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl,
N-methylaminomethyl, 2-(N-methylamino)ethyl,
l-methyl-2-(N,N-dimethylamino)ethyl, 2-(N,N-dimethylamino)ethyl,
2-(N,N-diethylamino)ethyl, 2-(N,N-diisopropylamino)ethyl,
3-(N,N-dimethylamino)propyl, 3-(N,N-diethylamino)propyl groups.
[0076] As a saturated 3- to 8-membered heteromonocyclic group
containing 1 to 2 nitrogen atoms group, for example, azetidinyl,
pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl,
piperazinyl morpholinyl, thiomorpholinyl groups (preferably a
saturated 5- to 6-membered heteromonocyclic group containing 1 to 2
nitrogen atoms group such as pyrrolidinyl, imidazolidinyl,
piperidinyl, piperidino, pyrazolidinyl and piperazinyl) can be
mentioned.
[0077] As a saturated 3- to 8-membered heteromonocyclic group
containing 1 to 2 nitrogen atoms-substituted lower alkyl group, a
lower alkyl (preferably, a linear or branched alkyl group having 1
to 6 carbon atoms) as illustrated above having 1 to 2 (preferably
one) a saturated 3- to 8-membered (preferably 5- to 6-membered)
heteromonocyclic group containing 1 to 2 nitrogen atoms as
illustrated above can be mentioned. More specifically, [(1-, 2- or
3-)azetidinyl]methyl, [(1-, 2- or 3-)pyrrolidinyl]methyl, [(1-, 2-
or 4-)-imidazolidinyl]methyl, [(1-, 3- or 4-)-pyrazolidinyl]methyl,
[(1-, 2-, 3- or 4-)-piperidyl]methyl, [(2-, 3- or
4-)morpholinyl]methyl, 2-[(1-, 2- or 3-)pyrrolidinyl]ethyl, 1-[(1-,
2- or 3-)-pyrrolidinyl]ethyl, 3-[(1-, 2- or 3-)piperidyl] propyl,
4-[(1-, 2- or 3-)pyrrolidinyl]butyl, 5-[(1-, 2- or
3-)-piperidyl]pentyl are included.
[0078] Examples of an alkylene group which may be substituted with
a hydroxy group (wherein the alkylene group may contain one oxygen
atom) include a linear or branched alkylene group (wherein the
alkylene group may contain one oxygen atom) having 1 to 12
(preferably 1 to 6) carbon atoms such as methylene, ethylene,
trimethylene, 2-methyltrimethylene, 2-hydroxytrimethylene,
3-hydroxytetramethylene, 3-methyltetramethylene,
2,2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene,
ethylmethylene, tetramethylene, pentamethylene, hexamethylene,
2-ethoxyethylene (--CH.sub.2CH.sub.2OCH.sub.2CH.sub.2--),
methoxymethylene (--CH.sub.2OCH.sub.2--), 1-ethoxyethylene
(--CH.sub.2CH.sub.2OCH(CH.sub.3)--), 2-methoxyethylene
(--CH.sub.2OCH.sub.2CH.sub.2--), 2-propoxyethylene
(--CH.sub.2CH.sub.2CH.sub.2OCH.sub.2CH.sub.2--),
3-isopropoxytrimethylene (--CH(CH.sub.3)
CH.sub.2OCH.sub.2CH.sub.2--), 4-butoxytetramethylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--),
5-pentyloxypentamethylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2OCH.sub.2CH.sub.2CH.sub.2CH.su-
b.2CH.sub.2--), 6-hexyloxyhexamethylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2OCH.sub.2CH.sub.2CH.su-
b.2CH.sub.2CH.sub.2CH.sub.2--), 1,1-dimethyl-2-methoxyethylene
(--CH.sub.2OCH.sub.2C(CH.sub.3).sub.2--),
2-methyl-3-ethoxytrimethylene
(--CH.sub.2CH.sub.2OCH.sub.2CH(CH.sub.3)CH.sub.2--),
3-methoxytrimethylene
(--CH.sub.2OCH.sub.2CH.sub.2CH.sub.2CH.sub.2--) groups.
[0079] Examples of a lower alkenylene group include a linear or
branched alkenylene group having 1 to 3 double bonds and 2 to 6
carbon atoms such as vinylene, 1-propenylene,
1-methyl-1-propenylene, 2-methyl-1-propenylene, 2-propenylene,
2-butenylene, 1-butenylene, 3-butenylene, 2-pentenylene,
1-pentenylene, 3-pentenylene, 4-pentenylene, 1,3-butadienylene,
1,3-pentadienylene, 2-pentene-4-ylene, 2-hexenylene, 1-hexenylene,
5-hexenylene, 3-hexenylene, 4-hexenylene,
3,3-dimethyl-1-propenylene, 2-ethyl-1-propenylene,
1,3,5-hexatrienylene, 1,3-hexadienylene, 1,4-hexadienylene
groups.
[0080] Examples of a lower alkylene group include a linear or
branched alkenylene group having 1 to 6 carbon atoms such as
methylene, ethylene, trimethylene, 2-methyltrimethylene,
3-methyltetramethylene, 2,2-dimethyltrimethylene,
1-methyltrimethylene, methylmethylene, ethylmethylene,
tetramethylene, pentamethylene and hexamethylene groups.
[0081] The heterocyclic compound represented by the above-described
general formula (1) can be produced in various kinds of methods,
but, for example, it can be produced by a method shown in the
following reaction formula.
##STR00017##
(wherein ring Q, A and R.sub.2 are the same as defined above, and
X.sub.1 represents a halogen atom or a group which causes a
substitution reaction the same as in a halogen atom).
[0082] Here, examples of a group which causes a substitution
reaction the same as in a halogen atom include a lower
alkanesulfonyloxy group, an arylsulfonyloxy group and an
aralkylsulfonyloxy group.
[0083] A halogen atom shown as X.sub.1 in the general formula (2)
is the same as defined above.
[0084] As a lower alkanesulfonyloxy group shown as X.sub.1,
examples include a linear or branched alkanesulfonyloxy group
having 1 to 6 carbon atoms such as methanesulfonyloxy,
ethanesulfonyloxy, n-propanesulfonyloxy, isopropanesulfonyloxy,
n-butanesulfonyloxy, tert-butanesulfonyloxy, n-pentanesulfonyloxy
and n-hexanesulfonyloxy groups.
[0085] As an arylsulfonyloxy group shown as X.sub.1, examples
include phenylsulfonyloxy and naphthylsulfonyloxy groups which may
have 1 to 3 substituents selected from the group consisting of a
linear or branched alkyl group having 1 to 6 carbon atoms, a linear
or branched alkoxy group having 1 to 6 carbon atoms, a nitro group
and a halogen atom on the phenyl ring, for example. Specific
examples of a phenylsulfonyloxy group which may have a substituent
include phenylsulfonyloxy, 4-methylphenylsulfonyloxy,
2-methylphenylsulfonyloxy, 4-nitrophenylsulphonyloxy,
4-methoxyphenylsulfonyloxy, 2-nitrophenylsulphonyloxy,
3-chlorophenylsulphonyloxy groups. Specific examples of a
naphthylsulfonyloxy group include .alpha.-naphthyl sulfonyloxy,
.beta.-naphthyl sulfonyloxy groups.
[0086] As an aralkylsulfonyloxy group shown as X.sub.1, examples
include a linear or branched alkanesulfonyloxy group having 1 to 6
carbon atoms and substituted with a phenyl group, a linear or
branched alkanesulfonyloxy group having 1 to 6 carbon atoms and
substituted with a naphthyl group, which groups which may have 1 to
3 substituents selected from the group consisting of a linear or
branched alkyl group having 1 to 6 carbon atoms, a linear or
branched alkoxy group having 1 to 6 carbon atoms, a nitro group and
a halogen atom on the phenyl ring, for example. Specific examples
of a phenylsulfonyloxy group substituted with a naphthyl group as
mentioned above include benzylsulfonyloxy,
2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy,
4-methylbenzylsulfonyloxy, 2-methylbenzylsulfonyloxy,
4-nitrobenzylsulfonyloxy, 4-methoxybenzylsulfonyloxy,
3-chlorobenzylsulfonyloxy groups. Specific examples of an
alkanesulfonyloxy group substituted with a naphthyl group as
mentioned above include .alpha.-naphthylmethyl sulfonyloxy,
.beta.-naphthylmethyl sulfonyloxy groups.
[0087] The reaction of a compound represented by the general
formula (2) and a compound represented by the general formula (3)
is performed without solvent or in an inert solvent in the absence
or presence of a basic compound.
[0088] Examples of an inert solvent include water; ethers such as
dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl
ether, ethylene glycol dimethyl ether; aromatic hydrocarbons such
as benzene, toluene, xylene; lower alcohols such as methanol,
ethanol, isopropanol; ketones such as acetone, methyl ethyl ketone;
polar solvents such as N,N-dimethylformamide (DMF),
dimethylsulfoxide (DMSO), hexamethylphosphoric triamide,
acetonitrile.
[0089] As a basic compound, known compounds can be widely used and
examples include alkali metal hydroxides such as sodium hydroxide,
potassium hydroxide, cesium hydroxide, lithium hydroxide; alkali
metal carbonates such as sodium carbonate, potassium carbonate,
cesium carbonate, lithium carbonate; alkaline metal hydrogen
carbonates such as lithium hydrogen carbonate, sodium hydrogen
carbonate, potassium bicarbonate; alkaline metals such as sodium,
potassium; inorganic bases such as sodium amide, sodium hydride,
potassium hydride and alkaline metal alcoholates such as sodium
methoxide, sodium ethoxide, potassium methoxide, potassium
ethoxide; organic bases such as triethylamine, tripropylamine,
pyridine, quinoline, piperidine, imidazole,
N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine,
dimethylaniline, N-methylmorpholine,
1,5-diazabicyclo[4.3.0]nonene-5 (DBN),
1,8-diazabicyclo[5.4.0]undecene-7 (DBU),
1,4-diazabicyclo[2.2.2]octane (DABCO).
[0090] As for these basic compounds, one kind of compound alone or
two or more in combination can be used.
[0091] The amount to be used of a basic compound is usually 0.5 to
10 times, preferably 0.5 to 6 times molar amount of a compound of
the general formula (2).
[0092] The above-described reaction can be performed with addition
of an alkaline metal iodide such as potassium iodide, sodium iodide
as a reaction accelerator, if necessary.
[0093] As for the ratio to be used of a compound of the general
formula (2) and a compound of the general formula (3) in the
above-mentioned reaction Formula 1, the latter may be usually at
least 0.5 times, preferably, 0.5 to 5 times molar amount of the
former.
[0094] The above-described reaction is performed usually from room
temperature to 200.degree. C., preferably from room temperature to
150.degree. C. and generally completed in about 1 to 30 hours.
##STR00018##
(wherein ring Q, R.sub.2 and A.sub.1 are the same as defined above.
X.sub.2 represents a hydroxy group, a halogen atom or a group which
causes a substitution reaction similar to a halogen atom).
[0095] The reaction of a compound represented by the general
formula (4) and a compound represented by the general formula (5a)
is performed under similar reaction condition as in the reaction of
a compound represented by the general formula (2) and a compound
represented by the general formula (3) in the above-mentioned
Reaction Formula 1.
[0096] In the case of a compound (5a) in which X.sub.2 represents a
hydroxy group, the reaction of a compound (4) and a compound (5a)
can be performed in an appropriate solvent in the presence of a
condensing agent.
[0097] As for the solvent usable here, specific examples include
halogenated hydrocarbons such as chloroform, dichloromethane,
dichloroethane, carbon tetrachloride; aromatic hydrocarbons such as
benzene, toluene, xylene; ethers such as diethyl ether, diisopropyl
ether, tetrahydrofuran, dimethoxyethane; esters such as methyl
acetate, ethyl acetate, isopropyl acetate; polar solvent such as
acetonitrile, pyridine, acetone, DMF, DMSO, hexamethylphosphoric
triamide or a mixed solvent of these.
[0098] As a condensing agent, azocarboxylates such as diethyl
azodicarboxylate and a mixture of phosphorus compounds such as
triphenylphosphine can be mentioned.
[0099] The amount of a condensing agent to be used is usually at
least equimolar, preferably equimolar to 2 times the amount of
compound (4).
[0100] The amount of compound (5a) to be used is usually at least
equimolar, preferably equimolar to 2 times the amount of compound
(4).
[0101] This reaction precedes usually 0 to 200.degree. C.,
preferably 0 to 150.degree. C. and generally completed in about 1
to 10 hours.
##STR00019##
[wherein R.sub.2 is the same as above, X.sub.3 represents a halogen
atom or a group which causes a substitution reaction similar to a
halogen atom, A.sub.2 represents a lower alkylene group, and
[0102] the ring Q1 represents a bicyclic group selected from the
group consisting of:
##STR00020##
(wherein the carbon-carbon bond [0103] represents a single bond or
a double bond);
[0104] the ring Q1 may have at least one substituent selected from
the group consisting of a lower alkyl group, a lower alkenyl group,
a lower alkynyl group, a hydroxy group, a lower alkoxy group, an
aryl group, an aryl lower alkyl group, an aryl lower alkoxy group,
a lower alkenyloxy group, a lower alkanoyl group, a lower
alkanoyloxy group, a cycloalkyl group, a cycloalkyl (lower) alkyl
group, a halogen atom, a carbamoyl group which may have a lower
alkyl group, a carboxy group, a lower alkoxycarbonyl group, an
amino group which may have a lower alkanoyl group, a nitro group, a
hydroxy lower alkyl group, an amino lower alkyl group which may
have a lower alkyl group, a thienyl group, a saturated 3- to
8-membered heteromonocyclic group containing 1 to 2 nitrogen
atoms-substituted lower alkyl group and an oxo group].
[0105] The reaction of a compound represented by the general
formula (6) and a compound represented by the general formula (5b)
is performed under similar reaction condition as in the reaction of
a compound represented by the general formula (2) and a compound
represented by the general formula (3) in the above-mentioned
Reaction Formula 1.
[0106] The compound represented by the general formula (2), which
is used as a starting material, can be produced, for example,
according to the following reaction Formula 4 and the compound
represented by the general formula (5) can be produced, for
example, according to the Reaction Formula 5 below
respectively.
##STR00021##
(wherein ring Q, A.sub.1, X.sub.1 and X.sub.3 are the same as
above)
[0107] The reaction of a compound represented by the general
formula (4) and a compound represented by the general formula (8)
is performed under similar reaction condition as in the reaction of
a compound represented by the general formula (4) and a compound
represented by the general formula (5a) in the above-mentioned
Reaction Formula 2.
##STR00022##
(wherein R.sub.2, A and X.sub.2 are the same as above, and X.sub.4
represents a halogen atom or a group which causes a substitution
reaction the same as in a halogen atom).
[0108] The reaction of a compound represented by the general
formula (3) and a compound represented by the general formula (9)
is performed under similar reaction condition as in the reaction of
a compound represented by the general formula (2) and a compound
represented by the general formula (3) in the above-mentioned
Reaction Formula 1. Both the compound of the general formula (3)
and the compound of the general formula (9) are well-known
compounds readily available.
[0109] In compound (1), a compound having a hydroxy group at ring Q
can be produced by treating a compound having a methoxy group at
ring Q in compound (1) in the presence of an acid in an appropriate
solvent or without solvent.
[0110] As for inert solvent usable here, examples include water;
aromatic hydrocarbons such as benzene, toluene, xylene; ethers such
as diethyl ether, tetrahydrofuran, dioxane, monoglyme, diglyme;
halogenated hydrocarbons such as dichloromethane, dichloroethane,
chloroform, carbon tetrachloride; lower alcohols such as methanol,
ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; fatty
acids such as acetic acid; esters such as ethyl acetate, methyl
acetate; ketones such as acetone, methyl ethyl ketone;
acetonitrile, pyridine, DMF, DMSO, hexamethylphosphoric triamide or
a mixed solvent of these.
[0111] As for the acid, examples include mineral acids such as
hydrobromic acid, hydrochloric acid, concentrated sulfuric acid;
fatty acids such as formic acid, acetic acid, organic acids such as
p-toluenesulfonic acid; Lewis acids such as aluminum chloride, zinc
chloride, iron chloride, tin chloride, boron trifluoride, boron
tribromide; iodides such as sodium iodide, potassium iodides; a
mixture of a Lewis acid and an iodide as mentioned above.
[0112] It is suitable that such an acid is usually used at 0.1 to
15 times, preferably 0.5 to 10 times molar amount of compound (1).
When the reaction is effected without solvent, the acid is usually
used in a large excess amount.
[0113] This reaction is performed usually 0 to 150.degree. C.,
preferably at around 0 to 100.degree. C., and generally completed
for about 0.5 to 75 hours.
[0114] The starting compounds used in each of the above reaction
formula may be suitable salt, the object compound obtained by each
of the reaction may form a suitable salt. Such suitable salts
include the preferable salts of compound (1) exemplified below.
[0115] The preferable salts of compound (1) are pharmacologically
acceptable salts and examples include metal salts such as alkali
metal salts (for example, sodium salt potassium salt, etc.),
alkaline earth metal salts (for example, calcium salt, magnesium
salt, etc.), salts of inorganic bases such as ammonium salt,
alkaline metal carbonates (for example, lithium carbonate,
potassium carbonate, sodium carbonate, cesium carbonate, etc.),
alkaline metal hydrogen carbonates (for example, lithium hydrogen
carbonate, sodium hydrogen carbonate, potassium bicarbonate, etc.),
alkali metal hydroxides (for example, lithium hydroxide, sodium
hydroxide, potassium hydroxide, cesium hydroxide, etc.); for
example, salts of organic bases such as tri(lower)alkylamine (for
example, trimethylamine, triethylamine, N-ethyldiisopropylamine),
pyridine, quinoline, piperidine, imidazole, picoline,
dimethylaminopyridine, dimethylaniline, N-(lower)alkyl-morpholine
(for example, N-methylmorpholine), 1,5-diazabicyclo[4.3.0]nonene-5
(DBN), 1,8-diazabicyclo[5.4.0]undecene-7 (DBU),
1,4-diazabicyclo[2.2.2] octane (DABCO); salts of inorganic acids
such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate,
phosphate; salts of organic acids such as formate, acetate,
propionate, oxalate, malonate, succinate, fumarate, maleate,
lactate, malate, citrate, tartrate, carbonate, picrate,
methanesulfonate, ethanesulfonate, p-toluenesulfonate,
glutamate.
[0116] In addition, compounds in the form in which solvate (for
example, hydrate, ethanolate, etc.) was added to the starting
compounds and object compound shown in each of the reaction
formulae are included in each of the general formulas. As a
preferable solvate, hydrate can be mentioned.
[0117] Each of the object compounds obtained by each of the general
formulas can be isolated and purified from the reaction mixture by,
for example, subjecting the reaction mixture to isolation operation
such as filtration, concentration and extraction after cooling to
separate a crude reaction product followed by conventional
purification operation such as column chromatography or
recrystallization.
[0118] The compound represented by the general formula (1) of the
present invention naturally encompasses isomers such as geometrical
isomer, stereoisomer and enantiomer.
[0119] The compound of the general formula (1) and a salt thereof
can be used in a common form of pharmaceutical preparation. The
pharmaceutical preparation is prepared by using usually used
diluent or excipient such as filler, extending agent, binder,
humectant, disintegrating agent, surfactant and lubricant. As for
this pharmaceutical preparation, various forms can be selected
depending on the purpose of treatment, and typical examples include
a tablet, pill, powder, solution, suspension, emulsion, granule,
capsule, suppository, and injection (solution, suspension).
[0120] For shaping in tablet form, various materials conventionally
well known as carrier in the art can be widely used. As examples,
excipient such as lactose, saccharose, sodium chloride, glucose,
urea, starch, calcium carbonate, kaolin, crystalline cellulose,
silicate; binder such as water, ethanol, propanol, simple syrup,
glucose solution, starch liquid, gelatine solution,
carboxymethylcellulose, shellac, methylcellulose, potassium
phosphate, polyvinylpyrrolidone; disintegrating agent such as dried
starch, sodium alginate, agar powder, laminaran powder, sodium
hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan
fatty acid ester, sodium lauryl sulfate, stearic acid
monoglyceride, starch, lactose; disintegration preventing agent
such as saccharose, stearin, cacao butter, hydrogenated oil;
sorbefacient such as quaternary ammonium base, sodium lauryl
sulfate; moisturizing agent such as glycerine, starch; absorbing
agent such as starch, lactose, kaolin, bentonite, colloidal silica;
lubricant such as purified talc, stearate, borate powder,
polyethylene glycol can be used, for example. Furthermore, the
tablet may be a tablet provided with conventional coating as
required, for example, sugar-coated tablet, gelatine encapsulated
tablet, enteric coating tablet, film coated tablet or double
tablet, multilayer tablet.
[0121] For shaping in pill form, various materials conventionally
well known as carrier in the art can be widely used. As examples,
excipient such as glucose, lactose, starch, cacao butter,
hydrogenated vegetable oil, kaolin, talc; binder such as powdered
gum arabic, powdered tragacanth, gelatine, ethanol; disintegrating
agent such as laminaran, agar can be used, for example.
[0122] For shaping in suppository form, various materials
conventionally well known as carrier can be widely used. Examples
thereof include polyethylene glycol, cacao butter, higher alcohol,
esters of higher alcohol, gelatine, semisynthesized glyceride, for
example.
[0123] A capsule is usually prepared according to a conventional
method by mixing active ingredient compounds with various carrier
exemplified above and filling them into a hard gelatin capsule, a
soft capsule or the like.
[0124] When prepared as injection liquid, it is preferable that
solution, emulsion and suspension are sterilized and isotonic to
the blood and for forming in these modes, any of those
conventionally used in the art as diluent can be used, and, for
example, water, ethyl alcohol, macrogol, propylene glycol,
ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol,
polyoxyethylene sorbitan fatty acid ester, etc. can be used.
[0125] The pharmaceutical preparation may contain common salt,
glucose or glycerine in an amount sufficient to prepare an isotonic
solution in this case, and conventional solubilizer, buffer,
soothing agent may be also added. Pigment, preservative, aromatic,
flavor, sweetening and other pharmaceuticals may be further
contained as required.
[0126] The amount of a compound of the general formula (1) or a
salt thereof to be contained in the pharmaceutical preparation of
the present invention is not particularly limited but usually about
1 to 70% by weight in the preparation composition is suitable and
preferably about 1 to 30% by weight.
[0127] There is not limitation in particular in the way of
administration of the pharmaceutical preparation of the present
invention and may be administered by a method in accordance with
specific form of the preparation, age, sex and the other conditions
of a patient, severity of disease, etc. For example, in the case of
tablet, pill, solution, suspension, emulsion, granule and capsule,
it is orally administered. In the case of injection, it is
intravenously administered alone or in a mixture with conventional
replacement fluid such as glucose and amino acids, and if
necessary, and the preparation alone may be also administered
intramuscularly, intracutaneously, subcutaneously or
interperitoneally. It is administered in rectum in the case of
suppository.
[0128] Applied dose of the pharmaceutical preparation of the
present invention is appropriately selected in accordance with
dosage regimen, age, sex and the other conditions of a patient,
severity of disease, etc., but it is suitable that the amount of
the active ingredient compound is usually about 0.1 to 10 mg per 1
kg of body weight per day. In addition, it is desirable that the
active ingredient compound is contained in the preparation of a
dosage unit form in the range of about 1 to 200 mg.
[0129] The compound of the present invention has D.sub.2 receptor
partial agonist effect, 5-HT.sub.2A receptor antagonist effect and
serotonin uptake inhibitory effect (or serotonin uptake inhibitory
effect).
[0130] The D.sub.2 receptor partial agonist effect suppresses
dopaminergic (DA) neurotransmission when it is enhanced, and
accelerates the DA neurotransmission when it is lowered and thus
has a function to stabilize the DA neurotransmission to a normal
state (dopamine system stabilizer). According to this function,
excellent clinically improving effect on the conditions based on
the DA abnormal neurotransmission (enhancement and lowering), for
example, improving effect on positive and negative symptoms,
improving effect on cognitive impairment, improving effect on
depressive symptom, etc. are developed without developing side
effects (See Michio Toru: Seishin-Igaku (Psychiatry), Vol. 46, pp.
855-864 (2004), Tetsuro Kikuchi. and Tsuyoshi Hirose: Nou-no-Kagaku
(Brain Science), Vol. 25, pp. 579-583 (2003) and Harrison, T. S.
and Perry, C. M.: Drugs 64: 1715-1736, 2004).
[0131] 5-HT.sub.2A receptor antagonist effect reduces
extrapyramidal side effects, develops superior clinical effects,
and is effective for improvement of negative symptoms, improvement
of cognitive impairment, improvement of depression condition,
improvement of insomnia, for example (See Jun Ishigooka and Ken
Inada: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical
Psychopharmacology), Vol. 4, pp. 1653-1664 (2001), Mitsukuni
Murasaki: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical
Psychopharmacology), Vol. 1, pp. 5-22 (1998), Puller, I. A. et al.,
Eur. J. Pharmacol., 407:39-46, 2000, and Meltzer, H. Y. et al,
Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1159-1172,
2003).
[0132] Serotonin uptake inhibitory effect (or serotonin reuptake
inhibitory effect) is effective for improving depressive symptoms,
for example (See Mitsukuni Murasaki: Rinsho-Seishin-Yakuri
(Japanese Journal of Clinical Psychopharmacology), Vol. 1, pp. 5-22
(1998)).
[0133] The compounds of the present invention are excellent in all
of these three effects, or remarkably excellent in one or two of
these effects.
[0134] In addition, some of the compounds of the present invention
have al receptor antagonist effect in addition to the
above-described effects. The .alpha..sub.1 receptor antagonist
effect is effective for improving positive symptoms of
schizophrenia (See Svensson, T. H.: Prog. Neuro-Psychopharmacol.
Biol. Psychiatry 27: 1145-1158, 2003).
[0135] Therefore, the compounds of the present invention have a
wide treatment spectrum for and excellent clinical effect on
schizophrenia and other central nervous system disorders.
[0136] Accordingly, the compounds of the present invention are
extremely effective for the treatment or prevention of central
nervous system disorders including the group consisting of
schizophrenia; refractory, intractable or chronic schizophrenia;
emotional disturbance; psychotic disorder; mood disorder; bipolar
disorder (for example, bipolar I type disorder and bipolar II type
disorder); depression; endogenous depression; major depression;
melancholy and refractory depression; dysthymic disorder;
cyclothymic disorder; anxiety disorder (for example, panic attack,
panic disorder, agoraphobia, social phobia, obsessive-compulsive
disorder, post-traumatic stress disorder, generalized anxiety
disorder, acute stress disorder, etc.); somatoform disorder (for
example, hysteria, somatization disorder, conversion disorder, pain
disorder, hypochondriasis, etc.); factitious disorder; dissociative
disorder; sexual disorder (for example, sexual dysfunction, sexual
desire disorder, sexual arousal disorder, erectile dysfunction,
etc.); eating disorder (for example, anorexia nervosa, bulimia
nervosa, etc.); sleep disorder; adjustment disorder;
substance-related disorder (for example, alcohol abuse, alcohol
intoxication, drug addiction, stimulant intoxication, narcotism,
etc.); anhedonia (for example, iatrogenic anhedonia, anhedonia of a
psychic or mental cause, anhedonia associated with depression,
anhedonia associated with schizophrenia, etc.); delirium; cognitive
impairment; cognitive impairment associated with Alzheimer's
disease, Parkinson's disease, and other neurodegenerative diseases;
cognitive impairment caused by Alzheimer's disease, Parkinson's
disease and associated neurodegenerative diseases; cognitive
impairment of schizophrenia; cognitive impairment caused by
refractory, intractable or chronic schizophrenia; vomiting; motion
sickness; obesity; migraine; pain (ache); mental retardation;
autism disorder (autism); Tourette's disorder; tic disorder;
attention-deficit/hyperactivity disorder; conduct disorder; and
Down's syndrome.
[0137] Furthermore, the compounds of the present invention have
little or no side effects and they are excellent in safety and
tolerability.
EXAMPLES
[0138] Hereinbelow, the present invention will be further made
clear with reference to Reference Examples, Examples,
Pharmacological Test Examples and Preparation Examples.
Reference Example 1
Preparation of 7-(4-chlorobutoxy)-1H-quinolin-2-one
[0139] After 14.7 g of potassium hydroxide was added to a methanol
(250 ml) suspension of 30 g of 7-hydroxy-1H-quinolin-2-one, which
was stirred at 50.degree. C. to form a solution, 65 ml of
1-bromo-4-chlorobutane was added thereto and refluxed for 8 hours.
After cooling to room temperature, precipitated crystals were
separated by filtration. They were purified by silica gel column
chromatography (dichloromethane:methanol=100:3), and 29.6 g of
7-(4-chlorobutoxy)-1H-quinolin-2-one was obtained in the form of a
white powder.
[0140] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0141] 1.95-2.15 (4H, m), 3.60-3.70 (2H, m), 4.10 (2H, t, J=5.6
Hz), 6.56 (1H, dd, J=9.0 Hz, 3.8 Hz), 6.81 (1H, dd, J=8.7 Hz, 2.4
Hz), 6.85 (1H, d, J=2.3 Hz), 7.45 (1H, d, J=8.7 Hz), 7.75 (1H, d,
J=9.4 Hz), 12.54 (1H, brs).
Reference Example 2
Preparation of 7-(4-chlorobutoxy)-4-methyl-1H-quinolin-2-one
[0142] 7-(4-chlorobutoxy)-4-methyl-1H-quinolin-2-one was prepared
from 7-hydroxy-4-methyl-1H-quinolin-2-one by a similar method as in
Reference Example 1.
[0143] White powder
[0144] .sup.1H-NMR (DMSO-d.sub.6).sup.8 ppm:
[0145] 1.80-2.00 (4H, m), 2.37 (3H, s), 3.72 (2H, t, J=6.0 Hz),
4.05 (2H, t, J=6.0 Hz), 6.20 (1H, s), 6.75-6.90 (2H, m), 7.60 (1H,
d, J=8.5 Hz), 11.42 (1H, brs).
Reference Example 3
Preparation of 7-methoxy-3-methyl-1H-quinolin-2-one
[0146] 30.7 ml of triethylsilane was added to a trifluoroacetic
acid (300 ml) solution of 13 g of
7-methoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde while being
stirred under ice-cooling and stirred at room temperature
overnight. The reaction solution was poured into ice water and
extracted with dichloromethane and, after washed with water, dried
over magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (dichloromethane:methanol=30:1), and 11.1 g of
7-methoxy-3-methyl-1H-quinolin-2-one was obtained in the form of a
white powder.
[0147] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0148] 2.02 (3H, s), 3.77 (3H, s), 6.70-6.80 (2H, m), 7.45 (1H, d,
J=8.4 Hz), 7.64 (1H, s), 11.56 (1H, brs).
Reference Example 4
Preparation of 7-hydroxy-3-methyl-H-quinolin-2-one
[0149] 47% hydrobromic acid (60 ml) suspension of 2.12 g of
7-methoxy-3-methyl-1H-quinolin-2-one was refluxed for six hours.
After cooling, water was added to the reaction solution and
precipitated crystals were separated by filtration. The crystals
were dissolved in a mixed solvent of dichloromethane and methanol
and dried over magnesium sulfate, and the solvent was evaporated
under reduced pressure and 1.7 g of
7-hydroxy-3-methyl-1H-quinolin-2-one was obtained in the form of a
brown powder.
[0150] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0151] 1.99 (3H, s), 6.57 (1H, dd, J=8.5 Hz, 2.5 Hz), 6.65 (1H, d,
J=2.5 Hz), 7.34 (1H, d, J=8.5 Hz), 7.58 (1H, s), 9.90 (1H, s),
11.48 (1H, brs).
Reference Example 5
Preparation of 7-(3-chloropropoxy)-3-methyl-1H-quinolin-2-one
[0152] By a similar method as in Reference Example 1,
7-(3-chloropropoxy)-3-methyl-1H-quinolin-2-one in the form of a
white powder was prepared from 7-hydroxy-3-methyl-1H-quinolin-2-one
using 1-bromo-3-chloropropane.
[0153] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0154] 2.05 (3H, s), 2.15-2.25 (2H, m), 3.81 (2H, t, J=6.5 Hz),
4.11 (2H, t, J=6.0 Hz), 6.75-6.85 (2H, m), 7.48 (1H, d, J=8.5 Hz),
7.67 (1H, s), 11.59 (1H, brs).
Reference Example 6
Preparation of 7-(4-chlorobutoxy)-3-methyl-1H-quinolin-2-one
[0155] By a similar method as in Reference Example 1,
7-(4-chlorobutoxy)-3-methyl-1H-quinolin-2-one in the form of a
white powder was prepared from 7-hydroxy-3-methyl-1H-quinolin-2-one
using 1-bromo-4-chlorobutane.
[0156] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0157] 1.80-1.95 (4H, m), 2.04 (3H, s), 3.72 (2H, t, J=6.0 Hz),
4.03 (2H, t, J=6.0 Hz), 6.75-6.80 (2H, m), 7.47 (1H, d, J=8.5 Hz),
7.66 (1H, s), 11.58 (1H, brs).
Reference Example 7
Preparation of 1-(4-chlorobutyl)-1H-quinolin-2-one
[0158] 0.30 g of sodium hydride (60% oily) was added to a
dimethylformamide (20 ml) solution of 1.0 g of 1H-quinolin-2-one
while being stirred under ice-cooling and stirred at room
temperature for 0.5 hour, and after that 1.6 ml of
1-bromo-4-chlorobutane was added and stirred at room temperature
for 14 hours. Water was added to the reaction solution, which was
then extracted with ethyl acetate and, after washed with water,
dried over magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate=3:1), and 1.02 g of
1-(4-chlorobutyl)-1H-quinolin-2-one was obtained in the form of
colorless oil.
[0159] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0160] 1.85-2.00 (4H, m), 3.60-3.65 (2H, m), 4.35 (2H, t, J=7.0
Hz), 6.70 (1H, d, J=9.5 Hz), 7.23 (1H, dd, J=8.6 Hz, 7.5 Hz), 7.38
(1H, d, J=8.9 Hz), 7.54-7.62 (2H, m), 7.68 (1H, d, J=9.5 Hz).
Reference Example 8
Preparation of 1-(5-chloropentyl)-1H-quinolin-2-one
[0161] By a similar method as in Reference Example 7,
1-(5-chloropentyl)-1H-quinolin-2-one in the form of colorless oil
was prepared from 1H-quinolin-2-one using
1-bromo-5-chloropentane.
[0162] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0163] 1.55-1.70 (2H, m), 1.75-1.95 (4H, m), 3.56 (2H, t, J=6.6
Hz), 4.31 (2H, t, J=7.8 Hz), 6.70 (1H, d, J=9.5 Hz), 7.23 (1H, dd,
J=7.3 Hz, 7.3 Hz), 7.35 (1H, d, J=8.9 Hz), 7.54-7.60 (2H, m), 7.67
(1H, d, J=9.4 Hz).
Reference Example 9
Preparation of
7-(4-chloro-(Z)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one
[0164] A mixture of 1.0 g of
7-hydroxy-3,4-dihydro-1H-quinolin-2-one, 1.7 g of potassium
carbonate, 3.2 ml of cis-1,4-dichloro-2-butene and 50 ml of
dimethylformamide was stirred at room temperature overnight. Water
was added to the reaction solution, which was then extracted with
ethyl acetate and, after washed with water, dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(n-hexane:ethyl acetate=3:1), and
7-(4-chloro-(Z)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one (1.3 g)
was obtained in the form of a white powder.
[0165] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0166] 2.62 (2H, t, J=6.3 Hz), 2.90 (2H, t, J=6.3 Hz), 4.16 (2H, d,
J=6.3 Hz), 4.62 (2H, d, J=4.6 Hz), 5.86-5.90 (2H, m), 6.31 (1H, d,
J=2.5 Hz), 6.54 (1H, dd, J=8.3 Hz, 2.5 Hz), 7.06 (1H, d, J=8.3 Hz),
7.56 (1H, brs).
Reference Example 10
Preparation of
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyric acid
methyl ester
[0167] 4.98 g of sodium iodide was added to an acetonitrile (70 ml)
solution of 5 g of 4-chloro-2-methylbutyric acid methyl ester and
it was refluxed for 3 hours. Water was added to the reaction
solution, which was then extracted with dichloromethane and, after
washed with water, dried over magnesium sulfate, and the solvent
was evaporated under reduced pressure. The residue was added to a
mixture of 4.33 g of 7-hydroxy-3,4-dihydro-1H-quinolin-2-one, 6.0 g
of potassium carbonate and dimethylformamide (90 ml) and stirred at
80.degree. C. for 6 hours. Water was added to the reaction
solution, which was then extracted with ethyl acetate and, after
washed with water, dried over magnesium sulfate, and the solvent
was evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (dichloromethane:methanol=100:3),
and 6.0 g of
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyric acid
methyl ester was obtained in the form of a yellow oil.
[0168] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0169] 1.23 (3H, d, J=7.1 Hz), 1.75-1.90 (1H, m), 2.10-2.25 (1H,
m), 2.55-2.65 (2H, m), 2.72 (1H, q, J=7.0 Hz), 2.80-2.90 (2H, m),
3.68 (3H, s), 3.95 (2H, t, J=6.2 Hz), 6.33 (1H, d, J=2.3 Hz), 6.49
(1H, dd, J=8.3 Hz, 2.21 Hz), 7.02 (1H, d, J=8.3 Hz), 8.41 (1H,
brs).
Reference Example 11
Preparation of
7-(4-hydroxy-3-methylbutoxy)-3,4-dihydro-1H-quinolin-2-one
[0170] 6 g of
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyric acid
methyl ester was added dropwise to a tetrahydrofuran (200 ml)
suspension of 1.6 g of lithium aluminum hydride while being stirred
under ice-cooling and stirred at the same temperature for 2 hours.
While being stirred under ice-cooling, saturated Rochelle salt
aqueous solution was added, which was extracted with diethyl ether
and, after washed with water, dried over magnesium sulfate, and the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography
(dichloromethane:methanol=40:1), and 2.8 g of
7-(4-hydroxy-3-methylbutoxy)-3,4-dihydro-1H-quinolin-2-one was
obtained in the form of a yellow oil.
[0171] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0172] 0.99 (3H, d, J=6.5 Hz), 1.60-2.05 (3H, m), 2.60-2.65 (2H,
m), 2.85-2.95 (2H, m), 3.55 (2H, t, J=5.3 Hz), 3.95-4.10 (2H, m),
6.38 (1H, d, J=2.5 Hz), 6.53 (1H, dd, J=8.3 Hz, 2.4 Hz), 7.04 (1H,
d, J=8.3 Hz), 8.59 (1H, brs).
Reference Example 12
Preparation of methanesulfonic acid
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl
ester
[0173] Methanesulfonyl chloride (1.0 ml) was added to a
dichloromethane (80 ml) solution of 2.8 g of 7-(4-hydroxy-3-methyl
butoxy)-3,4-dihydro-1H-quinolin-2-one and 2.4 ml of triethylamine
while being stirred under ice-cooling and stirred at room
temperature overnight. Water was added to the reaction solution,
which was then extracted with dichloromethane and, after washed
with water, dried over magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (dichloromethane:methanol=30:1),
and methanesulfonic acid
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl ester
(2.8 g) was obtained in the form of a green powder.
[0174] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0175] 1.07 (3H, d, J=6.8 Hz), 1.60-1.80 (1H, m), 1.90-2.00 (1H,
m), 2.15-2.25 (1H, m), 2.50-2.65 (2H, m), 2.90 (2H, t, J=7.3 Hz),
3.95-4.10 (2H, m), 4.10-4.20 (2H, m), 6.33 (1H, d, J=2.5 Hz), 6.51
(1H, dd, J=8.3 Hz, 2.5 Hz), 7.05 (1H, d, J=8.3 Hz), 8.16 (1H,
brs).
Reference Example 13
Preparation of
7-(4-bromo-(E)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one
[0176] By a similar method as in Reference Example 9,
7-(4-bromo-(E)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one in the
form of a white powder was prepared from
7-hydroxy-3,4-dihydro-1H-quinolin-2-one using
trans-1,4-dibromo-2-butene.
[0177] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0178] 2.61 (2H, t, J=7.5 Hz), 2.89 (2H, t, J=7.5 Hz), 3.98 (2H, d,
J=7.0 Hz), 4.51 (2H, d, J=4.8 Hz), 5.90-6.10 (2H, m), 6.43 (1H, d,
J=2.1 Hz), 6.51 (1H, dd, J=8.2 Hz, 2.1 Hz), 7.03 (1H, d, J=8.2 Hz),
9.35 (1H, brs).
Reference Example 14
Preparation of
7-(4-chlorobutoxy)-4-methyl-3,4-dihydro-1H-quinolin-2-one
[0179] Boron tribromide (1 M dichloromethane solution, 6.2 ml) was
added to a dichloromethane solution (5 ml) of 0.54 g of
7-methoxy-4-methyl-3,4-dihydro-1H-quinolin-2-one while being
stirred under ice-cooling and 0.23 g of precipitated crude crystals
were separated by filtration. 0.2 g of potassium carbonate and 0.45
ml of 1-bromo-4-chlorobutane were added to an acetonitrile (2.5
ml)-water (2.5 ml) solution of the crude crystals and refluxed for
6 hours. Water was added to the reaction solution, which was then
extracted with ethyl acetate and, after washed with water, dried
over magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (dichloromethane:methanol=50:1), and
7-(4-chlorobutoxy)-4-methyl-3,4-dihydro-1H-quinolin-2-one (0.29 g)
was obtained in the form of a white powder.
[0180] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0181] 1.28 (3H, d, J=7.0 Hz), 1.85-2.05 (4H, m), 2.35-2.45 (1H,
m), 2.65-2.75 (1H, m), 3.00-3.15 (1H, m), 3.62 (2H, t, J=6.0 Hz),
3.97 (2H, t, J=6.0 Hz), 6.32 (1H, d, J=2.5 Hz), 6.55 (1H, dd, J=8.5
Hz, 2.5 Hz), 7.08 (1H, d, J=8.5 Hz), 7.96 (1H, brs).
Reference Example 15
Preparation of
7-[2-(2-chloroethoxy)ethoxy]-3,4-dihydro-1H-quinolin-2-one
[0182] A mixture of 7.0 g of
7-hydroxy-3,4-dihydro-1H-quinolin-2-one, 7.1 g of potassium
carbonate, 30 ml of bis-2-chloroethyl ether and 400 ml of
acetonitrile was refluxed for 2 days. Water was added to the
reaction solution, which was then extracted with dichloromethane
and, after washed with water, dried over magnesium sulfate, and the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography
(dichloromethane:methanol=40:1), and 8.3 g of
7-[2-(2-chloroethoxy)ethoxy]-3,4-dihydro-1H-quinolin-2-one was
obtained in the form of a white powder.
[0183] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0184] 2.61 (2H, t, J=7.4 Hz), 2.90 (2H, t, J=7.4 Hz), 3.66 (2H, t,
J=5.8 Hz), 3.74-3.88 (4H, m), 4.11 (2H, t, J=4.7 Hz), 6.36 (1H, d,
J=2.2 Hz), 6.54 (1H, dd, J=8.3 Hz, 2.2 Hz), 7.05 (1H, d, J=8.3 Hz),
8.01 (1H, m).
Reference Example 16
Preparation of
6-(3-chloropropoxy)-3,4-dihydro-1H-quinolin-2-one
[0185] By a similar method as in Reference Example 9,
6-(3-chloropropoxy)-3,4-dihydro-1H-quinolin-2-one in the form of a
white powder was prepared from
6-hydroxy-3,4-dihydro-1H-quinolin-2-one using
1-bromo-3-chloropropane.
[0186] .sup.1H-NMR (CDCl.sub.3) ppm:
[0187] 2.15-2.35 (2H, m), 2.55-2.65 (2H, m), 2.90-3.00 (2H, m),
3.50-3.80 (2H, m), 4.00-4.10 (2H, m), 6.73 (3H, brs), 8.68 (1H,
brs).
Reference Example 17
Preparation of 6-(4-bromobutoxy)-3,4-dihydro-1H-quinolin-2-one
[0188] By a similar method as in Reference Example 9,
6-(4-bromobutoxy)-3,4-dihydro-1H-quinolin-2-one in the form of a
white powder was prepared from
6-hydroxy-3,4-dihydro-1H-quinolin-2-one using
1,4-dibromobutane.
[0189] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0190] 1.75-1.85 (2H, m), 1.90-2.00 (2H, m), 2.30-2.45 (2H, m),
2.75-2.85 (2H, m), 3.58 (2H, t, J=6.5 Hz), 3.91 (2H, t, J=6.5 Hz),
6.70-6.80 (3H, m), 9.88 (1H, brs).
Reference Example 18
Preparation of 1-(5-chloropentyl)-3,4-dihydro-1H-quinolin-2-one
[0191] By a similar method as in Reference Example 7,
1-(5-chloropentyl)-3,4-dihydro-1H-quinolin-2-one in the form of
colorless oil was prepared from 3,4-dihydro-1H-quinolin-2-one using
1-bromo-5-chloropentane.
[0192] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0193] 1.45-1.60 (2H, m), 1.60-1.75 (2H, m), 1.75-1.90 (2H, m),
2.60-2.70 (2H, m), 2.85-2.95 (2H, m), 3.54 (2H, d, J=6.6 Hz), 3.59
(2H, d, J=7.7 Hz), 6.76-7.04 (2H, m), 7.15-7.29 (2H, m).
Reference Example 19
Preparation of
2-(5-chloropentyl)-3,4-dihydro-2H-isoquinolin-1-one
[0194] By a similar method as in Reference Example 7,
2-(5-chloropentyl)-3,4-dihydro-2H-isoquinolin-1-one in the form of
brown oil was prepared from 3,4-dihydro-2H-isoquinolin-1-one using
1-bromo-5-chloropentane.
[0195] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0196] 1.50-2.00 (6H, m), 2.99 (2H, t, J=6.6 Hz), 3.52-3.60 (6H,
m), 7.17 (1H, d, J=7.3 Hz), 7.31-7.44 (2H, m), 8.07 (1H, dd, J=1.3
Hz, 7.5 Hz).
Reference Example 20
Preparation of
7-(3-chloropropoxy)-3,4-dihydro-2H-isoquinolin-1-one
[0197] By a similar method as in Reference Example 9,
7-(3-chloropropoxy)-3,4-dihydro-2H-isoquinolin-1-one in the form of
brown oil was prepared from
7-hydroxy-3,4-dihydro-2H-isoquinolin-1-one using
1-bromo-3-chloropropane.
[0198] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0199] 2.20-2.40 (2H, m), 2.90-3.00 (2H, m), 3.50-3.80 (4H, m),
4.15-4.20 (4H, m), 6.48 (1H, brs), 7.01 (1H, dd, J=4.0 Hz, 1.5 Hz),
7.13 (1H, d, J=4.0 Hz), 7.59 (1H, d, J=1.4 Hz).
Reference Example 21
Preparation of
7-hydroxy-2-methyl-3,4-dihydro-2H-isoquinolin-1-one
[0200] By a similar method as in Reference Example 4,
7-hydroxy-2-methyl-3,4-dihydro-2H-isoquinolin-1-one in the form of
a brown powder was prepared from
7-methoxy-2-methyl-3,4-dihydro-2H-isoquinolin-1-one.
[0201] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0202] 2.84 (2H, t, J=6.5 Hz), 3.01 (3H, s), 3.47 (2H, t, J=6.6
Hz), 6.85 (1H, dd, J=8.1 Hz, 2.5 Hz), 7.08 (1H, d, J=8.1 Hz), 7.29
(1H, d, J=2.5 Hz), 9.49 (1H, s).
Reference Example 22
Preparation of
7-(4-chlorobutoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one
[0203] By a similar method as in Reference Example 9,
7-(4-chlorobutoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one in the
form of a brown oil was prepared from
7-hydroxy-2-methyl-3,4-dihydro-2H-isoquinolin-1-one using
1-bromo-4-chlorobutane.
[0204] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0205] 1.90-2.00 (4H, m), 2.93 (2H, t, J=6.8 Hz), 3.15 (3H, s),
3.45-3.65 (4H, m), 4.04 (2H, t, J=5.8 Hz), 6.95 (1H, dd, J=8.3 Hz,
2.5 Hz), 7.07 (1H, d, J=8.3 Hz), 7.59 (1H, d, J=2.5 Hz).
Reference Example 23
Preparation of
7-(4-chlorobutoxy)-3,4-dihydro-2H-isoquinolin-1-one
[0206] By a similar method as in Reference Example 9,
7-(4-chlorobutoxy)-3,4-dihydro-2H-isoquinolin-1-one in the form of
a white powder was prepared from
7-hydroxy-3,4-dihydro-2H-isoquinolin-1-one using
1-bromo-4-chlorobutane.
[0207] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0208] 1.93-2.00 (4H, m), 2.88-2.96 (2H, m), 3.51-3.58 (2H, m),
3.62 (2H, t, J=6.2 Hz), 4.05 (2H, t, J=5.7 Hz), 6.25 (1H, s), 7.00
(1H, dd, J=8.3 Hz, 2.7 Hz), 7.13 (1H, d, J=8.3 Hz), 7.57 (1H, d,
J=2.7 Hz).
Reference Example 24
Preparation of 2-(4-chlorobutyl)-2H-isoquinolin-1-one
[0209] By a similar method as in Reference Example 7,
2-(4-chlorobutyl)-2H-isoquinolin-1-one in the form of a yellow oil
was prepared from 2H-isoquinolin-1-one using
1-bromo-4-chlorobutane.
[0210] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0211] 1.80-2.00 (4H, m), 3.59 (2H, t, J=6.3 Hz), 4.05 (2H, t,
J=7.0 Hz), 6.51 (1H, d, J=7.4 Hz), 7.05 (1H, d, J=7.4 Hz),
7.46-7.52 (2H, m), 7.63 (1H, m), 8.42 (1H, d, J=8.1 Hz).
Reference Example 25
Preparation of 7-(3-chloropropoxy)-2H-isoquinolin-1-one
[0212] By a similar method as in Reference Example 9,
7-(3-chloropropoxy)-2H-isoquinolin-1-one in the form of a white
powder was prepared from 7-hydroxy-2H-isoquinolin-1-one using
1-bromo-3-chloropropane.
[0213] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0214] 2.30 (2H, quint, J=6.1 Hz), 3.78 (2H, t, J=6.4 Hz), 4.28
(2H, t, J=5.9 Hz), 6.54 (1H, d, J=7.1 Hz), 7.06 (1H, d, J=6.6 Hz),
7.29 (1H, dd, J=8.7 Hz, 2.7 Hz), 7.51 (1H, d, J=8.7 Hz), 7.82 (1H,
d, J=2.7 Hz), 10.64 (1H, s).
Reference Example 26
Preparation of 7-(3-chloropropoxy)-2-ethyl-2H-isoquinolin-1-one
[0215] By a similar method as in Reference Example 7,
7-(3-chloropropoxy)-2-ethyl-2H-isoquinolin-1-one in the form of a
colorless oil was prepared from
7-(3-chloropropoxy)-2H-isoquinolin-1-one using ethyl iodide.
[0216] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0217] 1.38 (3H, t, J=7.2 Hz), 2.29 (2H, quint, J=6.1 Hz), 3.76
(2H, t, J=6.4 Hz), 4.07 (2H, q, J=7.2 Hz), 4.25 (2H, d, J=5.8 Hz),
6.48 (1H, d, J=7.3 Hz), 6.98 (1H, d, J=7.3 Hz), 7.23 (1H, dd, J=8.7
Hz, 2.7 Hz), 7.44 (1H, d, J=8.7 Hz), 7.85 (1H, d, J=2.6 Hz).
Reference Example 27
Preparation of 2-(4-chlorobutyl)-7-methoxy-2H-isoquinolin-1-one
[0218] By a similar method as in Reference Example 7,
2-(4-chlorobutyl)-7-methoxy-2H-isoquinolin-1-one in the form of
colorless oil was prepared from 7-methoxy-2H-isoquinolin-1-one
using 1-bromo-4-chlorobutane.
[0219] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0220] 1.64-2.00 (4H, m), 3.59 (2H, t, J=6.3 Hz), 3.93 (3H, s),
4.06 (2H, t, J=6.9 Hz), 6.49 (1H, d, J=7.3 Hz), 6.96 (1H, d, J=7.3
Hz), 7.25 (1H, dd, J=8.6 Hz, 2.7 Hz), 7.45 (1H, d, J=8.7 Hz), 7.83
(1H, d, J=2.7 Hz).
Reference Example 28
Preparation of 6-(3-chloropropoxy)-2H-isoquinolin-1-one
[0221] By a similar method as in Reference Example 9,
6-(3-chloropropoxy)-2H-isoquinolin-1-one in the form of a pale
yellow powder was prepared from 6-hydroxy-2H-isoquinolin-1-one
using 1-bromo-3-chloropropane.
[0222] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0223] 2.30 (2H, quint, J=6.0 Hz), 3.78 (2H, t, J=6.2 Hz), 4.24
(2H, t, J=5.9 Hz), 6.46 (1H, d, J=7.2 Hz), 6.93 (1H, d, J=2.4 Hz),
7.05-7.12 (2H, m), 8.33 (1H, d, J=8.9 Hz), 10.33 (1H, s).
Reference Example 29
Preparation of
7-(3-chloropropoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one
[0224] By a similar method as in Reference Example 9,
7-(3-chloropropoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one in
the form of a brown powder was prepared from
7-hydroxy-2-methyl-3,4-dihydro-2H-isoquinolin-1-one using
1-bromo-3-chloropropane.
[0225] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0226] 2.15-2.35 (2H, m), 2.85-3.00 (2H, m), 3.15 (3H, s),
3.50-3.80 (4H, m), 4.10-4.20 (2H, m), 6.96 (1H, dd, J=8.3 Hz, 2.7
Hz), 7.08 (1H, d, J=8.3 Hz), 7.62 (1H, d, J=2.7 Hz).
Reference Example 30
Preparation of 1-benzo[b]thiophen-4-yl-piperazine hydrochloride
[0227] A mixture of 14.4 g of 4-bromobenzo[b]thiophene, 29.8 g of
piperazine anhydride, 9.3 g of sodium t-butoxide, 0.65 g of
(R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 0.63 g
of dipalladium tris(dibenzylideneacetone) and 250 ml of toluene was
refluxed for 1 hour under nitrogen atmosphere. Water was poured to
the reaction solution, which was then extracted with ethyl acetate
and, after washed with water, dried over magnesium sulfate, and the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography
(dichloromethane:methanol:25% ammonia water=100:10:1), and 9.5 g of
1-benzo[b]thiophen-4-yl-piperazine in the form of yellow oil was
obtained.
[0228] 3.7 ml of concentrated hydrochloric acid was added to a
methanol solution of 9.5 g of 1-benzo[b]thiophen-4-yl-piperazine,
and the solvent was evaporated under reduced pressure. Ethyl
acetate was added to the residue and precipitated crystals were
filtrated and recrystallized from methanol and
1-benzo[b]thiophen-4-yl-piperazine hydrochloride was obtained as
colorless needle-like crystals.
[0229] Melting point 276-280.degree. C.
[0230] .sup.1H-NMR (DMSO-ds) .delta.ppm:
[0231] 3.25-3.35 (8H, m), 6.94 (1H, d, J=7.6 Hz), 7.30 (1H, dd,
J=7.8 Hz, 7.8 Hz), 7.51 (1H, d, J=5.5 Hz), 7.68 (1H, d, J=8.1 Hz),
7.73 (1H, d, J=5.5 Hz), 9.35 (2H, brs).
Reference Example 31
Preparation of tert-butyl
4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate
[0232] In the same manner as in Reference Example 30, tert-butyl
4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate was
prepared from tert-butyl 3-methylpiperazin-1-carboxylate and
4-bromobenzo[b]thiophene.
[0233] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0234] 1.85-1.95 (3H, m), 1.50 (9H, s), 2.8-2.9 (1H, m), 3.15-3.35
(2H, m), 3.4-3.5 (1H, m), 3.5-3.65 (1H, m), 3.65-3.7 (1H, m),
3.7-3.9 (1H, m), 6.98 (1H, d, J=7.5 Hz), 7.29 (1H, dd, J=8, 8 Hz),
7.38 (1H, d, J=5.5 Hz), 7.61 (1H, d, J=8 Hz).
Reference Example 32
Preparation of 1-benzo[b]thiophen-4-yl-2-methylpiperazine
dihydrochloride
[0235] A solution of 1.22 g (3.7 mmol) of tert-butyl
4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate in
methylene chloride (12 ml) was added to trifluoroacetic acid (6
ml), and the mixture was stirred at room temperature for 1 hour.
The reaction mixture was concentrated under reduced pressure, then
an aqueous solution of 5% potassium carbonate was added to the
residue and the resulting mixture was extracted with methylene
chloride. The organic phase was dried over magnesium sulfate and
concentrated under reduced pressure. Concentrated hydrochloric acid
(6 ml) and methanol (10 ml) were added to the residue and the
resulting mixture was concentrated under reduced pressure. The
residue was recrystallized from acetonitrile to obtain
1-benzo[b]thiophen-4-yl-2-methylpiperazine dihydrochloride (0.98 g)
as light brown powder.
[0236] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0237] 0.92 (3H, d, J=6.5 Hz), 2.8-3.6 (6H, m), 3.6-4.0 (1H, m),
5.3-6.8 (1H, m), 7.20 (1H, br), 7.38 (1H, dd, J=8, 8 Hz), 7.5-8.0
(3H, m), 9.4-10.1 (2H, m).
Reference Example 33
Preparation of l-benzo[b]thiophen-4-yl-3-methylpiperazine
dihydrochloride
[0238] In the same manner as in Reference Example 30,
1-benzo[b]thiophen-4-yl-3-methylpiperazine dihydrochloride was
prepared from 2-methylpiperazine and 4-bromobenzo[b]thiophene.
[0239] .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
[0240] 1.34 (3H, d, J=6.5 Hz), 2.85-2.95 (1H, m), 3.05-3.15 (1H,
m), 3.2-3.6 (6H, m), 6.97 (1H, d, J=7.5 Hz), 7.31 (1H, dd, J=8, 8
Hz), 7.54 (1H, d, J=5.5 Hz), 7.69 (1H, d, J=8 Hz), 7.75 (18, d,
J=5.5 Hz), 9.2-9.3 (1H, m), 9.64 (1H, br).
Reference Example 34
Preparation of ethyl
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate
[0241] 5.05 g (19.8 mmol) of 1-Benzo[b]thiophen-4-yl-piperazine
hydrochloride was added to an aqueous solution of sodium hydroxide,
and the mixture was extracted with methylene chloride. The organic
phase was dried over magnesium sulfate and concentrated under
reduced pressure. The residue was dissolved in 50 ml of ethanol and
ethyl acrylate (2.44 ml, 21.8 mmol) was added thereto, then the
reaction mixture was refluxed for 4 hours. The reaction mixture was
cooled to room temperature and concentrated under reduced pressure.
Isopropyl ether was added to the residue to filter out insoluble
matters. The insoluble matters were washed with isopropyl ether and
dried to obtain ethyl
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate (5.26 g) as
white powder.
Reference Example 35
Preparation of
3-(4-benzo[b]thiophen-4-yl-piperazine-1-yl)propan-1-ol
[0242] Lithium aluminum hydride (1.18 g, 24.8 mmol) was added to a
solution of 5.26 g (16.5 mmol) of ethyl
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate in
tetrahydrofuran (55 ml) with cooling in an ice-bath, followed by
stirring at room temperature for 4 hours. Water (1.2 ml), 15%
sodium hydroxide aqueous solution (1.2 ml), and water (3.6 ml) were
added to the reaction mixture in this order with stirring at room
temperature. Insoluble matters were removed by filtration, and the
filtrate was concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (n-hexane:ethyl
acetate=3:2.fwdarw.ethyl acetate), then concentrated and dried
under reduced pressure to obtain
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propane-1-ol (0.23 g) as
white powder.
[0243] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0244] 1.75-1.85 (2H, m), 2.74 (2H, t, J=5.8 Hz), 2.75-2.85 (4H,
m), 3.15-3.25 (4H, m), 3.85 (2H, t, J=5.3 Hz), 5.19 (1H, brs), 6.88
(1H, d, J=7.6 Hz), 7.27 (1H, dd, J=7.9, 7.8 Hz), 7.39 (2H, s), 7.56
(1H, d, J=8.0 Hz).
Reference Example 36
Preparation of 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl
acetate
[0245] 1.0 g (3.9 mmol) of l-Benzo[b]thiophen-4-yl-piperazine
hydrochloride was suspended in 20 ml of dimethylformamide (DMF),
and potassium carbonate (1.3 g, 9.4 mmol) and 4-bromobutyl acetate
(0.7 ml, 4.8 mmol) were added thereto followed by stirring at
80.degree. C. for 6 hours. The reaction mixture was cooled to room
temperature, then water was added thereto and the resulting mixture
was extracted with ethyl acetate. The organic phase was washed with
water, dried over magnesium sulfate, and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (methylene chloride:methanol=30:1), then
concentrated under reduced pressure to obtain
4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl acetate (0.72 g) as
light yellow oil.
Reference Example 37
Preparation of
4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butan-1-ol
[0246] Potassium carbonate (3.87 g, 28 mmol) was added to a
solution of 7.76 g (23.3 mmol) of butyl
4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)acetate in 90% methanol
(150 ml) followed by stirring at room temperature for 2 hours.
Water was added thereto and the reaction mixture was extracted with
methylene chloride. The organic phase was dried over magnesium
sulfate and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (n-hexane:ethyl
acetate=2:1.fwdarw.1:1), then concentrated under reduced pressure
to obtain 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butane-1-ol
(6.65 g) as colorless oil.
Reference Example 38
Preparation of
1-benzo[b]thiophen-4-yl-4-(3-chloropropyl)piperazine
[0247] 3.56 g (12.9 mmol) of
3-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol was suspended
in 30 ml of methylene chloride, and carbon tetrachloride (30 ml)
and triphenyl phosphine (4.06 g, 15.5 mmol) were added thereto
followed by stirring under reflux for 3 hours. The reaction mixture
was cooled to room temperature, then methanol and methylene
chloride were added thereto so as to make the mixture uniform.
Silica gel (30 g) was added to the uniform solution, and the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (silica gel: 300 g,
n-hexane:ethyl acetate=2:1), then concentrated under reduced
pressure to obtain
1-benzo[b]thiophen-4-yl-4-(3-chloropropyl)piperazine (2.36 g) as
colorless oil.
[0248] .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
[0249] 1.95-2.10 (2H, m), 2.60 (2H, t, J=7.2 Hz), 2.65-2.75 (4H,
m), 3.15-3.25 (4H, m), 3.65 (2H, t, J=6.6 Hz), 6.89 (1H, dd, J=7.6,
0.7 Hz), 7.27 (1H, dd, J=7.9, 7.8 Hz), 7.38 (1H, d, J=5.6 Hz), 7.41
(1H, d, J=5.7 Hz), 7.55 (1H, d, J=8.0 Hz)
Example 1
Preparation of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
butoxy]-1H-quinolin-2-one
[0250] A mixture of 9.0 g of 7-(4-chlorobutoxy)-1H-quinolin-2-one,
10 g of l-benzo[b]thiophene-4-yl-piperazine hydrochloride, 14 g of
potassium carbonate, 6 g of sodium iodide and 90 ml of
dimethylformamide was stirred for 2 hours at 80.degree. C. Water
was added to the reaction solution and precipitated crystals were
separated by filtration. The crystals were dissolved in a mixed
solvent of dichloromethane and methanol, dried over magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(dichloromethane:methanol=100:3). Recrystallized from ethanol, 13.6
g of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in the form of a white powder was obtained.
[0251] Melting point 183.5-184.5.degree. C.
[0252] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0253] 1.6-1.75 (2H, m), 1.75-1.9 (2H, m), 2.44 (2H, t, J=7 Hz),
2.5-2.8 (4H, m), 2.9-3.2 (4H, m), 4.06 (2H, t, J=6.5 Hz), 6.30 (1H,
d, J=9.5 Hz), 6.75-6.85 (2H, m), 6.88 (1H, d, J=7.5 Hz), 7.27 (1H,
dd, J=8 Hz, 8 Hz), 7.40 (1H, d, J=5.5 Hz), 7.55 (1H, d, J=9.5 Hz),
7.61 (1H, d, J=8 Hz), 7.69 (1H, d, J=5.5 Hz), 7.80 (1H, d, J=9.5
Hz), 11.59 (1H, bs).
Example 2
Preparation of 3-[2-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
ethoxy]-1H-quinolin-2-one
[0254] By a similar method as in Example 1,
3-[2-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)ethoxy]-1H-quinolin-2-one
was prepared from 3-(2-bromoethoxy)-1H-quinolin-2-one.
[0255] White powder (chloroform)
[0256] Melting point 201.9-204.5.degree. C.
[0257] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0258] 2.90-2.95 (4H, m), 3.10 (2H, t, J=5.9 Hz), 3.23-3.27 (4H,
m), 4.30 (2H, t, J=5.9 Hz), 6.90 (1H, d, J=7.7 Hz), 7.08 (1H, s),
7.15-7.32 (2H, m), 7.37-7.41 (4H, m), 7.47-7.49 (1H, m), 7.55 (1H,
d, J=8.1 Hz), 11.33 (1H, br).
Example 3
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-4-methyl-1H-quinoli-
n-2-one
[0259] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-4-methyl-1H-quinoli-
n-2-one was prepared from
7-(3-chloropropoxy)-4-methyl-1H-quinolin-2-one.
[0260] Slightly brown powder (ethyl acetate)
[0261] Melting point 202-208.degree. C.
[0262] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0263] 1.95-2.0 (2H, m), 2.37 (3H, s), 2.55 (2H, t, J=7 Hz),
2.6-2.7 (4H, m), 3.05-3.2 (4H, m), 4.09 (2H, t, J=6.5 Hz), 6.21
(1H, bs), 6.8-6.85 (2H, m), 6.90 (1H, d, J=7.5 Hz), 7.28 (1H, dd,
J=8 Hz, 8 Hz), 7.41 (1H, d, J=5.5 Hz), 7.6-7.7 (2H, m), 7.69 (1H,
d, J=5.5 Hz), 11.41 (1H, bs).
Example 4
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-4-methyl-1H-quinolin-
-2-one
[0264] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-4-methyl-1H-quinolin-
-2-one was prepared from
7-(4-chlorobutoxy)-4-methyl-1H-quinolin-2-one.
[0265] White powder (ethyl acetate)
[0266] Melting point 164-168.degree. C.
[0267] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0268] 1.6-1.7 (2H, m), 1.75-1.85 (2H, m), 2.37 (3H, s), 2.44 (2H,
t, J=7 Hz), 2.55-2.7 (4H, m), 3.0-3.2 (4H, m), 4.0-4.15 (2H, m),
6.20 (1H, bs), 6.8-6.85 (2H, m), 6.88 (1H, d, J=7.5 Hz), 7.27 (1H,
dd, J=8 Hz, 8 Hz), 7.40 (1H, d, J=5.5 Hz), 7.6-7.7 (2H, m), 7.69
(1H, d, J=5.5 Hz), 11.42 (1H, bs).
Example 5
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1H-quinoli-
n-2-one
[0269] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1H-quinoli-
n-2-one was prepared from
7-(3-chloropropoxy)-3-methyl-1H-quinolin-2-one.
[0270] White powder (ethyl acetate)
[0271] Melting point 185-187.degree. C.
[0272] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0273] 1.9-2.0 (2H, m), 2.04 (3H, s), 2.55 (2H, t, J=7 Hz),
2.6-2.75 (4H, m), 3.0-3.2 (4H, m), 4.07 (2H, t, J=6.5 Hz),
6.75-6.85 (2H, m), 6.90 (1H, d, J=7.5 Hz), 7.28 (1H, dd, J=8 Hz, 8
Hz), 7.40 (1H, d, J=5.5 Hz), 7.48 (1H, d, J=8.5 Hz), 7.61 (1H, d,
J=8 Hz), 7.65-7.7 (2H, m), 11.57 (1H, bs).
Example 6
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3-methyl-1H-quinolin-
-2-one
[0274] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3-methyl-1H-quinolin-
-2-one was prepared from
7-(4-chlorobutoxy)-3-methyl-1H-quinolin-2-one.
[0275] White powder (ethyl acetate)
[0276] Melting point 197-199.degree. C.
[0277] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0278] 1.6-1.7 (2H, m), 1.75-1.9 (2H, m), 2.04 (3H, s), 2.44 (2H,
t, J=7 Hz), 2.55-2.7 (4H, m), 3.0-3.15 (4H, m), 4.04 (2H, t, J=6.5
Hz), 6.75-6.85 (2H, m), 6.88 (1H, d, J=7.5 Hz), 7.27 (1H, dd, J=8
Hz, 8 Hz), 7.40 (1H, d, J=5.5 Hz), 7.47 (1H, d, J=8.5 Hz), 7.61
(1H, d, J=8 Hz), 7.65-7.75 (2H, m), 11.59 (1H, bs).
Example 7
Preparation of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
propoxy]-1H-quinolin-2-one
[0279] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-quinolin-2-one
was prepared from 7-(3-chloropropoxy)-1H-quinolin-2-one.
[0280] White powder (ethyl acetate-diethyl ether)
[0281] Melting point 204-207.degree. C.
[0282] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0283] 1.97 (2H, t, J=6.8 Hz), 2.50-2.60 (2H, m), 2.60-2.65 (4H,
m), 3.05-3.10 (4H, m), 4.08 (2H, t, J=6.4 Hz), 6.29 (1H, d, J=9.5
Hz), 6.75-6.85 (2H, m), 6.90 (1H, d, J=7.7 Hz), 7.25-7.30 (1H, m),
7.40 (1H, d, J=5.6 Hz), 7.55 (1H, d, J=8.4 Hz), 7.60-7.65 (1H, m),
7.69 (1H, d, J=5.5 Hz), 7.80 (1H, d, J=9.5 Hz), 11.57 (1H, s).
Example 8
Preparation of
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-1H-quinolin-2-one
hydrochloride
[0284] By a similar method as in Example 1,
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-1H-quinolin-2-one
was prepared from 1-(4-chlorobutyl)-1H-quinolin-2-one, and after it
was made into an ethanol solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration, and thereby
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-1H-quinolin-2-one
hydrochloride was obtained in the form of a white powder.
[0285] Melting point 282.0.degree. C. (decomposed)
[0286] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0287] 1.60-2.00 (4H, m), 3.10-3.40 (6H, m), 3.50-3.60 (4H, m),
4.31 (2H, t, J=7.4 Hz), 6.63 (1H, d, J=9.4 Hz), 6.96 (1H, d, J=7.6
Hz), 7.24-7.35 (2H, m), 7.48 (1H, d, J=5.4 Hz), 7.59-7.78 (5H, m),
7.93 (1H, d, J=9.5 Hz), 10.00-10.20 (1H, m).
Example 9
Preparation of
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-1H-quinolin-2-one
hydrochloride
[0288] By a similar method as in Example 1,
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-H-quinolin-2-one
was prepared from 1-(5-chloropentyl)-1H-quinolin-2-one, and after
it was made into an ethanol solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration, and thereby
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-1H-quinolin-2-one
hydrochloride was obtained in the form of a white powder.
[0289] Melting point 225.0-227.0.degree. C.
[0290] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0291] 1.35-1.50 (2H, m), 1.60-1.80 (4H, m), 3.10-3.30 (6H, m),
3.50-3.60 (4H, m), 4.27 (2H, t, J=7.4 Hz), 6.61 (1H, d, J=9.5 Hz),
6.96 (1H, d, J=7.5 Hz), 7.20-7.34 (2H, m), 7.47 (1H, d, J=5.5 Hz),
7.61-7.77 (5H, m), 7.91 (1H, d, J=9.5 Hz), 10.30-10.50 (1H, m).
Example 10
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one
[0292] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one was prepared from
7-(3-chloropropoxy)-3,4-dihydro-1H-quinolin-2-one.
[0293] White powder (methanol)
[0294] Melting point 163-165.degree. C.
[0295] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0296] 1.8-2.0 (2H, m), 2.41 (2H, t, J=7.5 Hz), 2.45-2.6 (2H, m),
2.6-2.7 (4H, m), 2.78 (2H, t, J=7.5 Hz), 2.95-3.2 (4H, m), 3.97
(2H, t, J=6.3 Hz), 6.46 (1H, d, J=2.3 Hz), 6.50 (1H, dd, J=2.4 Hz,
8.2 Hz), 6.90 (1H, d, J=7.6 Hz), 7.04 (1H, d, J=8.2 Hz), 7.27 (1H,
dd, J=7.8 Hz, 7.8 Hz), 7.40 (1H, d, J=5.6 Hz), 7.61 (1H, d, J=8.0
Hz), 7.69 (1H, d, J=5.5 Hz), 9.97 (1H, bs).
Example 11
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one
[0297] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one was prepared from
7-(4-chlorobutoxy)-3,4-dihydro-1H-quinolin-2-one.
[0298] White powder (methanol)
[0299] Melting point 147-148.degree. C.
[0300] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0301] 1.55-1.65 (2H, m), 1.65-1.8 (2H, m), 2.35-2.5 (4H, m),
2.55-2.7 (4H, m), 2.78 (2H, t, J=7.5 Hz), 3.0-3.15 (4H, m), 3.93
(2H, t, J=6.4 Hz), 6.44 (1H, d, J=2.5 Hz), 6.49 (1H, dd, J=2.5 Hz,
8.3 Hz), 6.89 (1H, d, J=7.5 Hz), 7.04 (1H, d, J=8.3 Hz), 7.27 (1H,
dd, J=7.8 Hz, 7.8 Hz), 7.35-7.45 (1H, m), 7.61 (1H, d, J=8.1 Hz),
7.68 (1H, d, J=5.6 Hz), 9.97 (1H, bs).
Example 12
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one hydrochloride
[0302] 1N hydrochloric acid ethanol solution was added to an
ethanol solution of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one prepared in Example 11, and precipitated crystals were
filtrated and recrystallized from 90% aqueous ethanol and
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one hydrochloride was obtained as slightly brown needle-like
crystals.
[0303] Melting point 237-239.degree. C.
[0304] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0305] 1.75-1.85 (2H, m), 1.85-2.0 (2H, m), 2.42 (2H, t, J=7.5 Hz),
2.79 (2H, t, J=7.5 Hz), 3.15-3.5 (6H, m), 3.5-3.7 (4H, m), 3.96
(2H, t, J=6 Hz), 6.46 (1H, d, J=2.5 Hz), 6.5-6.55 (1H, m), 6.97
(1H, d, J=7.5 Hz), 7.07 (1H, d, J=8.5 Hz), 7.32 (1H, dd, J=8 Hz, 8
Hz), 7.50 (1H, d, J=5.5 Hz), 7.71 (1H, d, J=8 Hz), 7.77 (1H, d,
J=5.5 Hz), 10.03 (1H, s), 10.65 (1H, br).
Example 13
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-(Z)-2-butenyloxy]-3,4-dihyd-
ro-1H-quinolin-2-one
[0306] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-(Z)-2-butenyloxy]-3,4-dihyd-
ro-1H-quinolin-2-one was prepared from
7-(4-chloro-(Z)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one.
[0307] White powder (methanol)
[0308] Melting point 68-70.degree. C.
[0309] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0310] 2.42 (2H, t, J=7.5 Hz), 2.64 (4H, br), 2.79 (2H, t, J=7.5
Hz), 2.9-3.25 (6H, m), 4.61 (2H, d, J=3 Hz), 5.65-5.9 (2H, m), 6.48
(1H, d, J=2.5 Hz), 6.54 (1H, dd, J=2.5, 8.5 Hz), 6.89 (1H, d, J=7.5
Hz), 7.06 (1H, d, J=8.5 Hz), 7.27 (1H, dd, J=8 Hz, 8 Hz), 7.40 (1H,
d, J=5.5 Hz), 7.61 (1H, d, J=8 Hz), 7.69 (1H, d, J=5.5 Hz), 10.01
(1H, bs).
Example 14
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-3-methylbutoxy]-3,4-dihydro-
-1H-quinolin-2-one hydrochloride
[0311] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-3-methylbutoxy]-3,4-dihydro-
-1H-quinolin-2-one was prepared from methanesulfonic acid
2-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl ester,
and after it was made into a methanol solution, 0.5N hydrochloric
acid methanol solution was added thereto, precipitated crystals
were separated by filtration, recrystallized from isopropyl alcohol
and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-3-methylbutoxy]-3,4-dihydro-
-1H-quinolin-2-one hydrochloride was obtained in the form of a
slightly yellow powder.
[0312] Melting point 217-219.degree. C. (decomposed)
[0313] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0314] 1.12 (3H, d, J=6.5 Hz), 1.55-1.7 (1H, m), 1.9-2.05 (1H, m),
2.2-2.3 (1H, m), 2.41 (2H, t, J=7.5 Hz), 2.79 (2H, t, J=7.5 Hz),
3.05-3.15 (1H, m), 3.15-3.25 (1H, m), 3.25-3.45 (4H, m), 3.45-3.55
(2H, m), 3.55-3.7 (2H, m), 3.9-4.1 (2H, m), 6.49 (1H, d, J=2.5 Hz),
6.54 (1H, dd, J=2.5 Hz, 8.5 Hz), 6.97 (1H, d, J=7.5 Hz), 7.06 (1H,
d, J=8.5 Hz), 7.33 (1H, dd, J=8 Hz, 8 Hz), 7.49 (1H, d, J=5.5 Hz),
7.70 (1H, d, J=8 Hz), 7.77 (1H, d, J=5.5 Hz), 10.03 (1H, bs), 10.66
(1H, br).
Example 15
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-(E)-2-butenyloxy]-3,4-dihyd-
ro-1H-quinolin-2-one
[0315] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-(E)-2-butenyloxy]-3,4-dihyd-
ro-1H-quinolin-2-one was prepared from
7-(4-bromo-(E)-2-butenyloxy)-3,4-dihydro-1H-quinolin-2-one.
[0316] White powder (dichloromethane-diisopropyl ether)
[0317] Melting point 147.8-149.7.degree. C.
[0318] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0319] 2.61 (2H, t, J=7.5 Hz), 2.65-2.75 (4H, m), 2.90 (2H, t,
J=7.5 Hz), 3.1-3.2 (6H, m), 4.52 (2H, d, J=4.3 Hz), 5.9-6.0 (2H,
m), 6.31 (1H, d, J=2.3 Hz), 6.55 (1H, dd, J=8.3 Hz, 2.3 Hz), 6.90
(1H, d, J=7.6 Hz), 7.05 (1H, d, J=8.3 Hz), 7.27 (1H, m), 7.37-7.41
(2H, m), 7.53-7.60 (2H, m).
Example 16
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-4-methyl-3,4-dihydro-
-1H-quinolin-2-one
[0320] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-4-methyl-3,4-dihydro-
-1H-quinolin-2-one was prepared from
7-(4-chlorobutoxy)-4-methyl-3,4-dihydro-1H-quinolin-2-one.
[0321] White powder (methanol)
[0322] Melting point 112-115.degree. C.
[0323] .sup.1H-NMR (DMSO-ds) .delta.ppm:
[0324] 1.14 (3H, d, J=7 Hz), 1.55-1.7 (2H, m), 1.7-1.8 (2H, m),
2.19 (1H, dd, J=7, 16 Hz), 2.43 (2H, t, J=7 Hz), 2.5-2.7 (5H, m),
2.9-3.0 (1H, m), 3.0-3.1 (4H, m), 3.94 (2H, t, J=6.5 Hz), 6.45 (1H,
d, J=2.5 Hz), 6.53 (1H, dd, J=2.5, 8.5 Hz), 6.89 (1H, d, J=7.5 Hz),
7.07 (1H, d, J=8.5 Hz), 7.27 (1H, dd, J=8 Hz, 8 Hz), 7.39 (1H, d,
J=5.5 Hz), 7.61 (1H, d, J=8 Hz), 7.69 (1H, d, J=5.5 Hz), 9.98 (1H,
bs).
Example 17
Preparation of
7-{2-[2-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)ethoxy]ethoxy}-3,4-dihydr-
o-1H-quinolin-2-one dihydrochloride
[0325] By a similar method as in Example 1,
7-{2-[2-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)ethoxy]ethoxy}-3,4-dihydr-
o-1H-quinolin-2-one was prepared from
7-[2-(2-chloroethoxy)ethoxy]-3,4-dihydro-1H-quinolin-2-one, and
after it was made into an ethanol solution, 1N hydrochloric acid
ethanol solution was added thereto, precipitated crystals were
separated by filtration, recrystallized from isopropyl
alcohol-diisopropyl ether and thereby
7-{2-[2-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)ethoxy]ethoxy}-3,4-dihydr-
o-1H-quinolin-2-one dihydrochloride was obtained in the form of a
white powder.
[0326] Melting point 172.3-177.2.degree. C.
[0327] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0328] 2.53 (2H, t, J=7.5 Hz), 2.80 (2H, t, J=7.5 Hz), 3.40 (2H,
m), 3.54-3.59 (2H, m), 3.79-3.94 (6H, m), 4.16-4.30 (6H, m),
6.50-6.53 (2H, m), 7.01 (1H, d, J=8.0 Hz), 7.36 (1H, dd, J=8 Hz, 8
Hz), 7.53-7.62 (2H, m), 7.82 (1H, d, J=8.0 Hz), 7.91 (1H, m), 8.02
(1H, brs), 13.31 (1H, brs).
Example 18
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-3,4-dihydro-
-1H-quinolin-2-one hydrochloride
[0329] 48 mg of sodium hydride (60% oily) was added to a solution
of 0.40 g of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H--
quinolin-2-one in dimethylformamide (5 ml) and tetrahydrofuran (5
ml) while being stirred under ice-cooling and stirred at room
temperature for 1 hour, and after that 0.07 ml of methyl iodide was
added and stirred at room temperature for 1 hour. Water was added
to the reaction solution, which was then extracted with ethyl
acetate and, after washed with water, dried over magnesium sulfate,
and the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography
(dichloromethane:methanol=30:1). The solvent was evaporated under
reduced pressure and 0.5N hydrochloric acid ethanol solution was
added thereto, precipitated crystals were separated by filtration,
and thereby 0.15 g of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-3,4-dihydro-
-1H-quinolin-2-one hydrochloride was obtained in the form of a
slightly yellow powder.
[0330] Melting point 275.6-277.6.degree. C.
[0331] .sup.1H-NMR (DMSO-d.sub.6) ppm:
[0332] 1.70-1.94 (4H, m), 2.48-2.52 (2H, m), 2.77 (2H, t, J=7.2
Hz), 3.15-3.30 (9H, m), 3.52-3.63 (4H, m), 4.03 (2H, t, J=6.0 Hz),
6.58-6.63 (2H, m), 6.96 (1H, d, J=7.5 Hz), 7.11 (1H, d, J=8.1 Hz),
7.31 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.48 (1H, d, J=5.5 Hz), 7.69 (1H,
d, J=8.0 Hz), 7.75 (1H, d, J=5.5 Hz), 10.61 (1H, br).
Example 19
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one hydrochloride
[0333] By a similar method as in Example 1,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quin-
olin-2-one was prepared from
6-(3-chloropropoxy)-3,4-dihydro-1H-quinolin-2-one, and after it was
made into a methanol solution, 0.5N hydrochloric acid methanol
solution was added thereto, precipitated crystals were separated by
filtration, recrystallized from a mixed solvent of ethyl
acetate-diethyl ether and thereby
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-
-1H-quinolin-2-one hydrochloride was obtained in the form of a
white powder.
[0334] Melting point 231-234.degree. C.
[0335] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0336] 2.20-2.30 (2H, m), 2.35-2.45 (2H, m), 2.83 (2H, t, J=7.5
Hz), 3.20-3.70 (10H, m), 4.02 (2H, t, J=5.9 Hz), 6.70-6.85 (3H, m),
6.96 (1H, d, J=7.6 Hz), 7.31 (1H, dd, J=7.9 Hz, 7.9 Hz), 7.48 (1H,
d, J=5.6 Hz), 7.69 (1H, d, J=8.1 Hz), 7.76 (1H, d, J=5.5 Hz), 9.93
(1H, brs), 10.90 (1H, brs).
Example 20
Preparation of
6-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one
[0337] By a similar method as in Example 1,
6-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-1H-quino-
lin-2-one was prepared from
6-(4-bromobutoxy)-3,4-dihydro-1H-quinolin-2-one.
[0338] White powder (ethyl acetate-diethyl ether)
[0339] Melting point 175-178.degree. C.
[0340] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0341] 1.65-1.90 (4H, m), 2.52 (2H, t, J=7.3 Hz), 2.55-2.65 (2H,
m), 2.65-2.75 (4H, m), 2.94 (2H, t, J=7.5 Hz), 3.15-3.25 (4H, m),
3.90-4.00 (2H, m), 6.65-6.75 (3H, m), 6.89 (1H, dd, J=0.7 Hz, 7.6
Hz), 7.27 (1H, dd, J=7.9 Hz, 7.9 Hz), 7.35-7.45 (2H, m), 7.55 (1H,
d, J=8.0 Hz), 8.02 (1H, brs).
Example 21
Preparation of
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-1H-quinol-
in-2-one hydrochloride
[0342] By a similar method as in Example 1,
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-1H-quinol-
in-2-one was prepared from
1-(4-chlorobutyl)-3,4-dihydro-1H-quinolin-2-one, and after it was
made into an ethanol solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration and thereby
1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-1H-quinol-
in-2-one hydrochloride was obtained in the form of a white
powder.
[0343] Melting point 257.0-259.0.degree. C.
[0344] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0345] 1.60-1.80 (4H, m), 2.54 (2H, t, J=8.3 Hz), 2.87 (2H, t,
J=7.9 Hz), 3.10-3.30 (6H, m), 3.50-3.60 (4H, m), 3.95 (2H, t, J=7.0
Hz), 6.94-7.04 (2H, m), 7.14-7.35 (4H, m), 7.48 (1H, d, J=5.6 Hz),
7.70 (1H, d, J=8.0 Hz), 7.76 (1H, d, J=5.6 Hz), 10.00-10.20 (1H,
m).
Example 22
Preparation of
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-3,4-dihydro-1H-quino-
lin-2-one hydrochloride
[0346] By a similar method as in Example 1,
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-3,4-dihydro-1H-quino-
lin-2-one was prepared from
1-(5-chloropentyl)-3,4-dihydro-1H-quinolin-2-one, and after it was
made into an ethanol solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration and thereby
1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-3,4-dihydro-1H-quino-
lin-2-one hydrochloride was obtained.
[0347] Melting point 242.0-244.0.degree. C.
[0348] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0349] 1.30-1.45 (2H, m), 1.50-1.65 (2H, m), 1.70-1.85 (2H, m),
2.53 (2H, t, J=8.2 Hz), 2.85 (2H, t, J=8.0 Hz), 3.10-3.30 (6H, m),
3.50-3.60 (4H, m), 3.91 (2H, t, J=7.3 Hz), 6.94-7.03 (2H, m),
7.13-7.34 (4H, m), 7.47 (1H, d, J=5.6 Hz), 7.69 (1H, d, J=8.0 Hz),
7.76 (1H, d, J=5.5 Hz), 10.30-10.50 (1H, m).
Example 23
Preparation of
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-2H-isoqui-
nolin-1-one hydrochloride
[0350] By a similar method as in Example 1,
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-2H-isoqui-
nolin-1-one was prepared from
2-(4-chlorobutyl)-3,4-dihydro-2H-isoquinolin-1-one, and after it
was made into an ethanol solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration, recrystallized from a mixed solvent of isopropyl
alcohol-ethanol and thereby
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-3,4-dihydro-2-
H-isoquinolin-1-one hydrochloride was obtained.
[0351] Melting point 257.5-265.5.degree. C.
[0352] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0353] 1.6-1.9 (4H, m), 2.98-3.60 (16H, m), 6.98 (1H, d, J=7.7 Hz),
7.30-7.38 (3H, m), 7.46-7.51 (2H, m), 7.71 (1H, d, J=8.2 Hz), 7.77
(1H, d, J=5.5 Hz), 7.89 (1H, d, J=7.7 Hz), 10.10 (1H, brs).
Example 24
Preparation of
2-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-3,4-dihydro-2H-isoqu-
inolin-1-one
[0354] By a similar method as in Example 1,
2-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-3,4-dihydro-2H-isoqu-
inolin-1-one was prepared from
2-(5-chloropentyl)-3,4-dihydro-2H-isoquinolin-1-one.
[0355] White powder (ethyl acetate-diisopropyl ether)
[0356] Melting point 91.8-93.3.degree. C.
[0357] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0358] 1.32-1.37 (2H, m), 1.56-1.64 (4H, m), 2.38 (2H, t, J=7.6
Hz), 2.62 (4H, m), 2.92 (2H, t, J=6.5 Hz), 3.09-3.11 (4H, m),
3.47-3.55 (4H, m), 6.81 (1H, d, J=7.5 Hz), 7.08-7.11 (2H, m),
7.17-7.35 (4H, m), 7.47 (1H, d, J=8.0 Hz), 8.01 (1H, dd, J=7.5 Hz,
1.4 Hz).
Example 25
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one
[0359] By a similar method as in Example 1,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one was prepared from
6-(3-chloropropoxy)-3,4-dihydro-2H-isoquinolin-1-one.
[0360] White powder (ethyl acetate-diethyl ether)
[0361] Melting point 203-205.degree. C.
[0362] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0363] 2.00-2.10 (2H, m), 2.60-2.70 (2H, m), 2.74 (4H, brs), 2.96
(2H, t, J=6.5 Hz), 3.20 (4H, brs), 3.50-3.60 (2H, m), 4.11 (2H, t,
J=6.3 Hz), 6.09 (1H, brs), 6.73 (1H, s), 6.85-6.95 (2H, m),
7.25-7.30 (1H, m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.1 Hz), 8.01
(1H, d, J=8.6 Hz).
Example 26
Preparation of
6-[3-(4-benzol[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihyd-
ro-2H-isoquinolin-1-one
[0364] By a similar method as in Example 18,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one was prepared from
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one using methyl iodide.
[0365] White powder (ethyl acetate-diethyl ether)
[0366] Melting point 110-113.degree. C.
[0367] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0368] 2.05 (2H, t, J=6.9 Hz), 2.65 (2H, t, J=7.3 Hz), 2.74 (4H,
brs), 2.97 (2H, t, J=6.7 Hz), 3.14 (3H, s), 3.21 (4H, brs), 3.54
(2H, t, J=6.7 Hz), 4.11 (2H, t, J=6.4 Hz), 6.68 (1H, s), 6.86 (1H,
dd, J=2.3 Hz, 8.6 Hz), 6.91 (1H, d, J=7.7 Hz), 7.25-7.30 (1H, m),
7.40 (1H, d, J=5.5 Hz), 7.42 (1H, d, J=5.5 Hz), 7.56 (1H, d, J=7.9
Hz), 8.03 (1H, d, J=8.6 Hz).
Example 27
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-
-2H-isoquinolin-1-one
[0369] By a similar method as in Example 18,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-
-2H-isoquinolin-1-one was prepared from
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one using ethyl iodide.
[0370] White powder (ethyl acetate-diethyl ether)
[0371] Melting point 128-131.degree. C.
[0372] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0373] 1.21 (3H, t, J=7.2 Hz), 2.05 (2H, t, J=6.9 Hz), 2.65 (2H, t,
J=7.3 Hz), 2.74 (4H, brs), 2.96 (2H, t, J=6.6 Hz), 3.21 (4H, brs),
3.54 (2H, t, J=6.7 Hz), 3.62 (2H, q, J=7.2 Hz), 4.11 (2H, t, J=6.3
Hz), 6.68 (1H, d, J=1.7 Hz), 6.86 (1H, dd, J=2.3 Hz, 8.2 Hz), 6.91
(1H, d, J=7.7 Hz), 7.25-7.30 (1H, m), 7.40 (1H, d, J=5.5 Hz), 7.42
(1H, d, J=5.5 Hz), 7.56 (1H, d, J=7.8 Hz), 8.03 (1H, d, J=8.6
Hz).
Example 28
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one
[0374] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one was prepared from
7-(3-chloropropoxy)-3,4-dihydro-2H-isoquinolin-1-one.
[0375] White powder (ethyl acetate-diethyl ether)
[0376] Melting point 176-179.degree. C.
[0377] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0378] 2.00-2.10 (2H, m), 2.64 (2H, t, J=7.3 Hz), 2.73 (4H, brs),
2.94 (2H, t, J=6.6 Hz), 3.20 (4H, brs), 3.50-3.60 (2H, m), 4.12
(2H, t, J=6.3 Hz), 5.92 (1H, brs), 6.90 (1H, d, J=7.7 Hz), 7.03
(1H, dd, J=2.8 Hz, 8.3 Hz), 7.13 (1H, d, J=8.3 Hz), 7.25-7.30 (1H,
m), 7.39 (1H, d, J=5.5 Hz), 7.42 (1H, d, J=5.5 Hz), 7.55 (1H, d,
J=8.1 Hz), 7.62 (1H, d, J=2.7 Hz).
Example 29
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one
[0379] By a similar method as in Example 18,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one was prepared from
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one using methyl iodide.
[0380] White powder (ethanol)
[0381] Melting point 115-117.degree. C.
[0382] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0383] 1.95-2.10 (2H, m), 2.64 (2H, t, J=7.3 Hz), 2.70-2.80 (4H,
m), 2.94 (2H, t, J=6.7 Hz), 3.10-3.25 (4H, m), 3.16 (3H, s), 2.54
(2H, t, J=6.7 Hz), 4.11 (2H, t, J=6.5 Hz), 6.90 (1H, d, J=7.0 Hz),
6.98 (1H, dd, J=2.7 Hz, 8.3 Hz), 7.08 (1H, d, J=8.3 Hz), 7.28 (1H,
dd, J=7.9 Hz, 7.9 Hz), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.1 Hz),
7.63 (1H, d, J=2.6 Hz).
Example 30
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one hydrochloride
[0384] After
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one was made into an ethanol solution, 1N
hydrochloric acid ethanol solution was added thereto, precipitated
crystals were separated by filtration, recrystallized from ethanol
and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one hydrochloride was obtained in the form of a
white powder.
[0385] Melting point 229-233.degree. C.
[0386] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0387] 2.20-2.30 (2H, m), 2.89 (2H, t, J=6.7 Hz), 3.01 (3H, s),
3.21 (2H, t, J=6.9 Hz), 3.30-3.60 (8H, m), 3.60-3.70 (2H, m), 4.11
(2H, t, J=6.0 Hz), 6.97 (1H, d, J=7.7 Hz), 7.06 (1H, dd, J=2.8 Hz,
8.3 Hz), 7.22 (1H, d, J=7.9 Hz), 7.31 (1H, dd, J=7.8 Hz, 7.8 Hz),
7.41 (1H, d, J=2.7 Hz), 7.49 (1H, d, J=5.5 Hz), 7.69 (1H, d, J=8.1
Hz), 7.76 (1H, d, J=5.5 Hz), 10.70 (1H, brs).
Example 31
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-
-2H-isoquinolin-1-one dihydrochloride
[0388] By a similar method as in Example 18,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-
-2H-isoquinolin-1-one was prepared from
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoq-
uinolin-1-one using ethyl iodide, and after it was made into a
methanol solution, 0.5N hydrochloric acid methanol solution was
added thereto, precipitated crystals were separated by filtration,
recrystallized from a mixed solvent of methanol-ethyl acetate and
thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-
-2H-isoquinolin-1-one dihydrochloride was obtained in the form of a
white powder.
[0389] Melting point 210-213.degree. C.
[0390] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0391] 1.09 (3H, t, J=7.1 Hz), 2.20-2.30 (2H, m), 2.87 (2H, t,
J=6.5 Hz), 3.20-3.70 (14H, m), 4.11 (2H, t, J=5.9 Hz), 6.96 (1H, d,
J=7.7 Hz), 7.00-7.10 (1H, m), 7.22 (1H, d, J=8.3 Hz), 7.25-7.35
(1H, m), 7.41 (1H, d, J=2.7 Hz), 7.48 (1H, d, J=5.5 Hz), 7.69 (1H,
d, J=7.7 Hz), 7.76 (11H, d, J=5.5 Hz), 11.08 (1H, brs).
Example 32
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-2-methyl-3,4-dihydro-
-2H-isoquinolin-1-one hydrochloride
[0392] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-2-methyl-3,4-dihydro-
-2H-isoquinolin-1-one was prepared from
7-(4-chlorobutoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one, and
after it was made into a methanol solution, 0.5N hydrochloric acid
methanol solution was added thereto, precipitated crystals were
separated by filtration, recrystallized from a mixed solvent of
methanol-ethyl acetate and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-2-methyl-3,4-dihydro-
-2H-isoquinolin-1-one hydrochloride was obtained in the form of a
white powder.
[0393] Melting point 213-218.degree. C.
[0394] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0395] 1.70-2.00 (4H, m), 2.88 (2H, t, J=6.6 Hz), 3.01 (3H, s),
3.10-3.70 (12H, m), 4.03 (2H, t, J=5.8 Hz), 6.95 (1H, d, J=7.5 Hz),
7.04 (1H, dd, J=2.8 Hz, 8.5 Hz), 7.20 (1H, d, J=8.4 Hz), 7.31 (1H,
dd, J=7.8 Hz, 7.8 Hz), 7.39 (1H, d, J=2.7 Hz), 7.48 (1H, d, J=5.7
Hz), 7.69 (1H, d, J=8.1 Hz), 7.75 (1H, d, J=5.5 Hz), 10.71 (1H,
brs).
Example 33
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoqu-
inolin-1-one hydrochloride
[0396] By a similar method as in Example 1,
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoqu-
inolin-1-one was prepared from
7-(4-chlorobutoxy)-3,4-dihydro-2H-isoquinolin-1-one, and after it
was made into an ethyl acetate solution, 1N hydrochloric acid
ethanol solution was added thereto, precipitated crystals were
separated by filtration, recrystallized from ethyl acetate and
thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3,4-dihydro-2H-isoqu-
inolin-1-one hydrochloride was obtained in the form of a white
powder.
[0397] Melting point 223.8-226.8.degree. C.
[0398] .sup.1H-NMR (DMSO-ds) .delta.ppm:
[0399] 1.81-1.93 (4H, m), 2.83 (2H, t, J=6.5 Hz), 3.16-3.32 (8H,
m), 3.43-3.64 (4H, m), 4.06 (2H, t, J=5.9 Hz), 6.97 (1H, d, J=7.6
Hz), 7.07 (1H, dd, J=8.3 Hz, 2.7 Hz), 7.24 (1H, d, J=7.7 Hz), 7.32
(1H, dd, J=7.9 Hz, 7.9 Hz), 7.39 (1H, d, J=2.7 Hz), 7.50 (1H, d,
J=5.6 Hz), 7.71 (1H, d, J=8.0 Hz), 7.77 (1H, d, J=5.5 Hz), 7.95
(1H, s), 10.62 (1H, s).
Example 34
Preparation of
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-2H-isoquinolin-1-one
[0400] By a similar method as in Example 1,
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-2H-isoquinolin-1-one
was prepared from 2-(4-chlorobutyl)-2H-isoquinolin-1-one.
[0401] Pale brown powder (ethyl acetate-diisopropyl ether)
[0402] Melting point 141.1-142.7.degree. C.
[0403] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0404] 1.62 (2H, m), 1.87 (2H, m), 2.50 (2H, t, J=7.4 Hz),
2.66-2.71 (4H, m), 3.16-3.19 (4H, m), 4.06 (2H, t, J=7.2 Hz), 6.50
(1H, d, J=7.3 Hz), 6.89 (1H, d, J=7.7 Hz), 7.08 (1H, d, J=7.3 Hz),
7.24-7.65 (7H, m), 8.44 (1H, d, J=7.9 Hz).
Example 35
Preparation of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
propoxy]-2H-isoquinolin-1-one
[0405] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e was prepared from 7-(3-chloropropoxy)-2H-isoquinolin-1-one.
[0406] White powder (ethyl acetate)
[0407] Melting point 220.1-222.5.degree. C.
[0408] 1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0409] 1.99 (2H, quint, J=6.6 Hz), 2.57 (2H, t, J=7.0 Hz), 2.66
(4H, brs), 3.09 (4H, brs), 4.16 (2H, t, J=6.3 Hz), 6.52 (1H, d,
J=7.1 Hz), 6.90 (1H, d, J=7.4 Hz), 7.04 (1H, dd, J=6.9 Hz, 6.9 Hz),
7.26 (1H, d, J=7.9 Hz), 7.33 (1H, dd, J=8.8 Hz, 2.8 Hz), 7.41 (1H,
d, J=5.5 Hz), 7.59-7.63 (3H, m), 7.69 (1H, d, J=5.5 Hz), 11.21 (1H,
d, J=4.9 Hz).
Example 36
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one hydrochloride
[0410] By a similar method as in Example 18,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one was prepared from
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e using methyl iodide, and after it was made into an ethyl acetate
solution, 1N hydrochloric acid ethanol solution was added thereto,
precipitated crystals were separated by filtration, recrystallized
from ethyl acetate and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one hydrochloride was obtained in the form of a white
powder.
[0411] Melting point 227.6-230.2.degree. C.
[0412] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0413] 2.31 (2H, quint, J=7.0 Hz), 3.20-3.40 (6H, m), 3.52 (3H, s),
3.54-3.70 (4H, m), 4.23 (2H, t, J=5.8 Hz), 6.60 (1H, d, J=7.3 Hz),
6.99 (1H, d, J=7.7 Hz), 7.30-7.38 (3H, m), 7.51 (1H, d, J=5.6 Hz),
7.63-7.73 (3H, m), 7.78 (1H, d, J=5.5 Hz), 10.88 (1H, s).
Example 37
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-2H-isoquino-
lin-1-one hydrochloride
[0414] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-2H-isoquino-
lin-1-one was prepared from
7-(3-chloropropoxy)-2-ethyl-2H-isoquinolin-1-one, and after it was
made into an ethyl acetate solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration, recrystallized from ethyl acetate and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-2H-isoquino-
lin-1-one hydrochloride was obtained in the form of a white
powder.
[0415] Melting point 229.9-231.2.degree. C.
[0416] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0417] 1.25 (3H, t, J=7.1 Hz), 2.29 (2H, brs), 3.14-3.49 (6H, m),
3.56-3.72 (4H, m), 4.00 (2H, q, J=7.2 Hz), 4.23 (2H, t, J=5.9 Hz),
6.62 (1H, d, J=7.3 Hz), 6.99 (1H, d, J=7.6 Hz), 7.27-7.39 (3H, m),
7.51 (1H, d, J=5.6 Hz), 7.62-7.73 (3H, m), 7.78 (1H, d, J=5.5 Hz),
10.38 (1H, s).
Example 38
Preparation of
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-methoxy-2H-isoquino-
lin-1-one hydrochloride
[0418] By a similar method as in Example 1,
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-methoxy-2H-isoquino-
lin-1-one was prepared from
2-(4-chlorobutyl)-7-methoxy-2H-isoquinolin-1-one, and after it was
made into an ethyl acetate solution, 1N hydrochloric acid ethanol
solution was added thereto, precipitated crystals were separated by
filtration, recrystallized from ethyl acetate and thereby
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-methoxy-2H-isoquino-
lin-1-one hydrochloride was obtained in the form of a white
powder.
[0419] Melting point 243.5-245.6.degree. C.
[0420] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0421] 1.78 (4H, brs), 3.10-3.28 (6H, m), 3.56 (4H, t, J=9.6 Hz),
3.87 (3H, s), 4.04 (2H, t, J=5.3 Hz), 6.64 (1H, d, J=7.3 Hz), 6.96
(1H, d, J=7.6 Hz), 7.30 (1H, d, J=8.0 Hz), 7.34 (1H, dd, J=8.6 Hz,
2.9 Hz), 7.41 (1H, d, J=7.3 Hz), 7.49 (1H, d, J=5.6 Hz), 7.63 (1H,
d, J=8.6 Hz), 7.69 (1H, dd, J=8.0 Hz, 8.0 Hz), 7.77 (1H, d, J=5.5
Hz), 10.60 (1H, s).
Example 39
Preparation of
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-hydroxy-2H-isoquino-
lin-1-one hydrobromide
[0422] Boron tribromide (2M dichloromethane solution, 1.0 ml) was
added to a dichloromethane (50 ml) solution of
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-methoxy-2H-isoquino-
lin-1-one (0.16 g) while being stirred under ice-cooling and
stirred at room temperature for 3 days. Water was added to the
reaction solution, which was then stirred at room temperature for
0.5 hour. Precipitated crystals were separated by filtration,
recrystallized from ethyl acetate and thereby
2-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-7-hydroxy-2H-isoquino-
lin-1-one hydrobromide (0.13 g) was obtained in the form of a white
powder.
[0423] Melting point 273.6-275.7.degree. C.
[0424] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0425] 1.75 (4H, brs), 3.08 (2H, t, J=11.1 Hz), 3.16-3.28 (4H, m),
3.59 (2H, t, J=10.5 Hz), 4.01 (2H, brs), 6.58 (1H, d, J=7.3 Hz),
6.97 (1H, d, J=7.5 Hz), 7.19 (1H, dd, J=8.6 Hz, 2.6 Hz), 7.29-7.36
(2H, m), 7.49-7.65 (3H, m), 7.71 (1H, d, J=8.0 Hz), 7.78 (1H, d,
J=5.5 Hz), 9.50 (1H, brs), 9.95 (1H, s).
Example 40
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e
[0426] By a similar method as in Example 1,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e was prepared from 6-chloropropoxy-2H-isoquinolin-1-one.
[0427] White powder (ethyl acetate)
[0428] Melting point 228.8-230.7.degree. C.
[0429] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0430] 1.98 (2H, quint, J=6.7 Hz), 2.56 (2H, t, J=7.0 Hz), 2.65
(4H, brs), 3.09 (4H, brs), 4.17 (2H, t, J=6.3 Hz), 6.47 (1H, d,
J=7.1 Hz), 6.90 (1H, d, J=7.6 Hz), 7.05 (1H, dd, J=8.8 Hz, 2.4 Hz),
7.10-7.15 (2H, m), 7.28 (1H, d, J=7.8 Hz), 7.41 (1H, d, J=5.5 Hz),
7.62 (1H, d, J=8.0 Hz), 7.70 (1H, d, J=5.5 Hz), 8.07 (1H, d, J=8.8
Hz), 11.03 (1H, s).
Example 41
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one hydrochloride
[0431] By a similar method as in Example 18,
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one was prepared from
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-on-
e using methyl iodide, and after it was made into an ethyl acetate
solution, 1N hydrochloric acid ethanol solution was added thereto,
precipitated crystals were separated by filtration, recrystallized
from ethyl acetate and thereby
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquin-
olin-1-one hydrochloride was obtained in the form of a white
powder.
[0432] Melting point 241.4-244.8.degree. C.
[0433] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0434] 2.31 (2H, t, J=7.6 Hz), 3.46 (3H, s), 3.19-3.70 (10H, m),
4.24 (2H, t, J=5.9 Hz), 6.54 (1H, d, J=7.4 Hz), 6.99 (1H, d, J=7.6
Hz), 7.10 (1H, dd, J=8.8 Hz, 2.4 Hz), 7.15 (1H, d, J=2.3 Hz), 7.33
(1H, dd, J=7.9 Hz, 7.9 Hz), 7.45 (1H, d, J=7.1 Hz), 7.51 (1H, d,
J=5.5 Hz), 7.71 (1H, d, J=8.0 Hz), 7.78 (1H, d, J=5.5 Hz), 8.14
(1H, d, J=8.8 Hz), 10.86 (1H, s).
Example 42
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
hydrochloride
[0435] 1N hydrochloric acid aqueous solution was added to a
solution of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from 70%
ethanol and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
hydrochloride was obtained in the form of a white powder.
[0436] Melting point 238-241.degree. C.
[0437] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0438] 1.80-2.00 (4H, m), 3.20-3.45 (6H, m), 3.50-3.60 (4H, m),
4.06 (2H, t, J=5.6 Hz), 6.28 (1H, d, J=9.5 Hz), 6.75-6.85 (2H, m),
6.95 (1H, d, J=7.5 Hz), 7.30 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.47 (1H,
d, J=5.7 Hz), 7.56 (1H, d, J=8.4 Hz), 7.68 (1H, d, J=8.1 Hz),
7.70-7.85 (2H, m), 10.92 (1H, brs), 11.61 (1H, brs).
Example 43
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
sulfate
[0439] Dilute sulphuric acid was added to a solution of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from 60%
ethanol and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
sulfate was obtained in the form of a white powder.
[0440] Melting point 248-251.degree. C.
[0441] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0442] 1.80-1.95 (4H, m), 2.50-4.00 (10H, m), 4.00-4.10 (2H, m),
6.30 (1H, d, J=8.2 Hz), 6.75-6.85 (2H, m), 6.97 (1H, d, J=7.6 Hz),
7.31 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.49 (1H, d, J=5.6 Hz), 7.55-7.60
(1H, m), 7.70 (11H, d, J=8.0 Hz), 7.75-7.85 (2H, m), 9.25-9.75 (1H,
br), 11.62 (1H, brs).
Example 44
Preparation of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)
butoxy]-1H-quinolin-2-one maleate
[0443] A methanol solution of maleic acid was added to a solution
of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from 80%
ethanol and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
maleate was obtained in the form of a white powder.
[0444] Melting point 181.6-182.8.degree. C.
[0445] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0446] 1.87 (2H, brs), 3.26-3.47 (10H, m), 4.10 (2H, s), 6.07 (2H,
s), 6.33 (1H, d, J=9.5 Hz), 6.82-6.84 (2H, m), 6.99 (1H, d, J=7.6
Hz), 7.33 (1H, d, J=7.8 Hz), 7.51 (1H, d, J=5.5 Hz), 7.59 (1H, d,
J=9.3 Hz), 7.70-7.85 (3H, m), 11.65 (1H, s).
Example 45
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
fumarate
[0447] Fumaric acid was added to a solution of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from ethanol
and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-H-quinolin-2-one
fumarate was obtained in the form of a white powder.
[0448] Melting point 209-211.degree. C.
[0449] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0450] 1.60-1.90 (4H, m), 2.47-2.50 (2H, m), 2.60-2.75 (4H, m),
3.00-3.15 (4H, m), 4.05 (2H, t, J=6.3 Hz), 6.28 (1H, d, J=9.4 Hz),
6.60 (2H, s), 6.76-6.82 (2H, m), 6.88 (1H, d, J=7.4 Hz), 7.26 (1H,
dd, J=7.9 Hz, 7.8 Hz), 7.39 (1H, d, J=5.9 Hz), 7.54 (1H, d, J=9.4
Hz), 7.61 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=5.5 Hz), 7.79 (1H, d,
J=9.5 Hz), 11.58 (1H, brs).
Example 46
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
citrate
[0451] Citric acid was added to a solution of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from 50%
ethanol and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
citrate was obtained in the form of a white powder.
[0452] Melting point 183-185.degree. C.
[0453] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0454] 1.50-2.00 (4H, m), 2.58 (2H, s), 2.62 (2H, s), 2.75-2.85
(2H, m), 2.95-3.05 (4H, m), 3.10-3.20 (4H, m), 4.05 (2H, t, J=5.3
Hz), 6.28 (1H, d, J=9.4 Hz), 6.75-6.85 (2H, m), 6.90 (1H, d, J=7.6
Hz), 7.27 (1H, dd, J=7.9 Hz, 7.9 Hz), 7.42 (1H, d, J=5.5 Hz), 7.55
(1H, d, J=9.3 Hz), 7.64 (1H, d, J=8.0 Hz), 7.71 (1H, d, J=5.5 Hz),
7.79 (1H, d, J=9.5 Hz), 11.59 (1H, brs).
Example 47
Preparation of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
p-toluenesulfonate
[0455] p-Toluenesulfonic acid monohydrate was added to a solution
of
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
in methanol and dichloromethane and the solvent was evaporated
under reduced pressure. The residue was recrystallized from
methanol and thereby
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
p-toluenesulfonate was obtained in the form of a white powder.
[0456] Melting point 121.0-125.0.degree. C.
[0457] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0458] 1.73-2.00 (4H, m), 2.28 (3H, s), 3.07 (2H, J=11.0 Hz),
3.23-3.43 (4H, m), 3.62 (4H, t, J=15.0 Hz), 4.09 (2H, t, J=7.1 Hz),
6.31 (1H, dd, J=9.5 Hz, 2.3 Hz), 6.80 (1H, s), 6.84 (1H, d, J=2.3
Hz), 6.98 (1H, d, J=7.5 Hz), 7.11 (2H, d, J=8.0 Hz), 7.33 (1H, dd,
J=7.5 Hz, 7.5 Hz), 7.46-7.52 (3H, m), 7.58 (1H, d, J=9.5 Hz), 7.72
(1H, d, J=7.5 Hz), 7.78 (1H, d, J=11.3 Hz), 7.81 (1H, d, J=9.5 Hz),
9.31-9.49 (1H, m), 11.54-11.63 (1H, m).
Example 48
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one sulfate
[0459] Dilute sulphuric acid was added to a solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one in ethanol and dichloromethane and the
solvent was evaporated under reduced pressure. The residue was
recrystallized from 85% ethanol and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one sulfate was obtained in the form of a white
powder.
[0460] Melting point 222-224.degree. C.
[0461] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0462] 2.10-2.30 (2H, m), 2.91 (2H, t, J=6.6 Hz), 3.03 (3H, s),
3.05-4.00 (12H, m), 4.13 (2H, t, J=5.9 Hz), 6.99 (1H, d, J=7.5 Hz),
7.09 (1H, dd, J=2.7 Hz, 8.3 Hz), 7.24 (1H, d, J=8.4 Hz), 7.33 (1H,
dd, J=7.8 Hz, 7.8 Hz), 7.44 (1H, d, J=2.7 Hz), 7.51 (1H, d, J=5.5
Hz), 7.72 (1H, d, J=8.1 Hz), 7.78 (1H, d, J=5.5 Hz), 9.00-10.05
(1H, br).
Example 49
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one fumarate
[0463] Fumaric acid was added to an ethanol solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one and the solvent was evaporated under reduced
pressure. The residue was recrystallized from 70% ethanol and
thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one fumarate was obtained in the form of a pale
yellow powder.
[0464] Melting point 149-151.degree. C.
[0465] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0466] 1.85-2.00 (2H, m), 2.58 (2H, t, J=7.2 Hz), 2.65-2.75 (4H,
m), 2.88 (2H, t, J=6.7 Hz), 3.01 (3H, s), 3.05-3.15 (4H, m), 3.50
(2H, t, J=6.7 Hz), 4.05 (2H, t, J=6.3 Hz), 6.60 (2H, s), 6.89 (1H,
d, J=7.6 Hz), 7.03 (1H, dd, J=8.3 Hz, 2.7 Hz), 7.19 (1H, d, J=8.3
Hz), 7.27 (1H, dd, J=7.9 Hz, 7.8 Hz), 7.38 (1H, d, J=3.0 Hz), 7.40
(1H, d, J=5.9 Hz), 7.61 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=5.5
Hz).
Example 50
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one difumarate
[0467] Fumaric acid was added to an ethanol solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one and the solvent was evaporated under reduced
pressure. The residue was recrystallized from 90% ethanol and
thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one difumarate was obtained in the form of white
prism crystal.
[0468] Melting point 188-189.degree. C.
[0469] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0470] 1.85-2.00 (2H, m), 2.60 (2H, t, J=7.0 Hz), 2.65-2.75 (4H,
m), 2.88 (2H, t, J=6.6 Hz), 3.01 (3H, s), 3.00-3.10 (4H, m), 3.50
(2H, t, J=6.7 Hz), 4.05 (2H, t, J=6.4 Hz), 6.61 (4H, s), 6.90 (1H,
d, J=7.5 Hz), 7.04 (1H, dd, J=8.2 Hz, 2.8 Hz), 7.19 (1H, d, J=8.4
Hz), 7.27 (1H, dd, J=7.9 Hz, 7.8 Hz), 7.38 (1H, d, J=3.0 Hz), 7.40
(1H, d, J=6.2 Hz), 7.61 (1H, d, J=8.0 Hz), 7.69 (1H, d, J=5.5
Hz).
Example 51
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one maleate
[0471] A methanol solution of maleic acid was added to a solution
of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one in methanol and dichloromethane and the
solvent was evaporated under reduced pressure. The residue was
recrystallized from ethanol and ethyl acetate and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one maleate was obtained in the form of a white
powder.
[0472] Melting point 134.6-135.5.degree. C.
[0473] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0474] 2.17 (2H, brs), 2.91 (2H, t, J=6.7 Hz), 3.03 (3H, s), 3.33
(10H, brs), 3.52 (2H, t, J=6.7 Hz), 4.12 (2H, t, J=5.9 Hz), 6.04
(2H, s), 6.99 (1H, d, J=7.6 Hz), 7.07 (1H, dd, J=8.3 Hz, 2.6 Hz),
7.24 (1H, d, J=8.4 Hz), 7.32 (1H, dd, J=7.9 Hz, 7.9 Hz), 7.43 (1H,
d, J=2.6 Hz), 7.50 (1H, d, J=5.5 Hz), 7.71 (1H, d, J=7.9 Hz), 7.77
(1H, d, J=5.5 Hz).
Example 52
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one p-toluenesulfonate
[0475] p-Toluenesulfonic acid monohydrate was added to a solution
of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one in methanol and dichloromethane and the
solvent was evaporated under reduced pressure. The residue was
recrystallized from ethanol and ethyl acetate and thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one p-toluenesulfonate was obtained in the form
of a white powder.
[0476] Melting point 173.0-175.5.degree. C.
[0477] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0478] 2.00-2.33 (2H, m), 2.28 (3H, s), 2.91 (2H, t, J=6.6 Hz),
3.02 (3H, s), 3.00-3.16 (2H, m), 3.29-3.80 (10H, m), 4.12 (2H, t,
J=5.5 Hz), 6.99 (1H, d, J=7.9 Hz), 7.06 (1H, d, J=2.5 Hz), 7.11
(2H, d, J=7.9 Hz), 7.24 (1H, d, J=8.0 Hz), 7.33 (1H, dd, J=8.0 Hz,
8.0 Hz), 7.44 (1H, d, J=2.5 Hz), 7.48 (1H, d, J=7.9 Hz), 7.51 (1H,
d, J=5.5 Hz), 7.72 (1H, d, J=8.0 Hz), 7.82 (1H, d, J=5.5 Hz),
9.39-9.58 (1H, m)
Example 53
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one
[0479] By a similar method as in Example 1,
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one was prepared from
7-(3-chloropropoxy)-2-methyl-3,4-dihydro-2H-isoquinolin-1-one.
[0480] White powder (ethanol)
[0481] Melting point 115-117.degree. C.
[0482] .sup.1H-NMR (CDCl.sub.3) .delta.ppm:
[0483] 1.95-2.10 (2H, m), 2.64 (2H, t, J=7.3 Hz), 2.70-2.80 (4H,
m), 2.94 (2H, t, J=6.7 Hz), 3.10-3.25 (4H, m), 3.16 (3H, s), 2.54
(2H, t, J=6.7 Hz), 4.11 (2H, t, J=6.5 Hz), 6.90 (1H, d, J=7.0 Hz),
6.98 (1H, dd, J=2.7 Hz, 8.3 Hz), 7.08 (1H, d, J=8.3 Hz), 7.28 (1H,
dd, J=7.9 Hz, 7.9 Hz), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.1 Hz),
7.63 (1H, d, J=2.6 Hz).
Example 54
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one methanesulfonate
[0484] Methanesulfonic acid was added to an ethanol solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one and the solvent was evaporated under reduced
pressure. The residue was recrystallized from 80% ethanol and
thereby
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydr-
o-2H-isoquinolin-1-one methanesulfonate was obtained in the form of
pale yellow prism crystal.
[0485] Melting point 147-149.degree. C.
[0486] .sup.1H-NMR (DMSO-d.sub.6) .delta.ppm:
[0487] 2.10-2.25 (2H, m), 2.29 (3H, s), 2.90 (2H, t, J=6.7 Hz),
3.02 (3H, s), 3.05-3.15 (2H, m), 3.40-3.50 (4H, m), 3.51 (2H, t,
J=6.7 Hz), 3.55-3.70 (4H, m), 4.12 (2H, t, J=6.0 Hz), 6.98 (1H, d,
J=7.6 Hz), 7.06 (1H, dd, J=8.3 Hz, 2.7 Hz), 7.23 (1H, d, J=8.4 Hz),
7.32 (1H, dd, J=7.9 Hz, 7.8 Hz), 7.43 (1H, d, J=2.7 Hz), 7.50 (1H,
d, J=5.5 Hz), 7.71 (1H, d, J=8.1 Hz), 7.77 (1H, d, J=5.5 Hz),
9.40-9.60 (1H, m).
Example 55
Preparation of
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinoline
hydrochloride
[0488] 4-Chloroquinoline (230 mg, 1.58 mmol),
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol (310 mg, 1.05
mmol), and potassium carbonate (220 mg, 1.6 mmol) were added to
dimethylformamide (10 ml), followed by stirring at 80.degree. C.
for 5 hours. The reaction mixture was cooled to room temperature,
then water was added thereto and the reaction mixture was extracted
with ethyl acetate. The organic phase was washed with water, dried
over magnesium sulfate, and concentrated under reduced pressure
after filtration. The residue was purified by basic silica gel
column chromatography (n-hexane:ethyl acetate=4:1), and
concentrated under reduced pressure. The resulting residue was
dissolved in ethanol (3 ml), and 1N-HCl--ethanol solution (1 ml)
was added thereto. Insoluble matters produced were filtered out and
dried to obtain
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinoline
hydrochloride (360 mg, yield: 78%) as light yellow powder.
[0489] Melting point: 240-242.degree. C.
Example 56
Preparation of
3-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]isoquinoline
hydrochloride
[0490] 3-Hydroxyisoquinoline (170 mg, 1.17 mmol),
1-benzo[b]thiophen-4-yl-4-(3-chloropropyl)piperazine (290 mg, 1.0
mmol), and potassium carbonate (200 mg, 1.45 mmol) were added to
dimethylformamide (8 ml), followed by stirring at 80.degree. C. for
7 hours. The reaction mixture was cooled to room temperature, then
water was added thereto and the reaction mixture was extracted with
ethyl acetate. The organic phase was washed with water, dried over
magnesium sulfate, and concentrated under reduced pressure after
filtration. The residue was purified by basic silica gel column
chromatography (n-hexane:ethyl acetate=9:1), and concentrated under
reduced pressure. The resulting residue was dissolved in ethanol (2
ml), and 1N-HCl--ethanol solution (0.5 ml) was added thereto.
Insoluble matters produced were filtered out and dried to obtain
3-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]isoquinoline
hydrochloride (160 mg, yield: 37%) as white powder.
[0491] Melting point: 227-229.degree. C.
Example 57
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-6-methoxy-3,4-dihyd-
roisoquinoline dihydrochloride
[0492] PS-triphenylphosphine (110 mg, 3 mmol/g) and dibenzyl
azodicarboxylate (70 mg, 0.3 mmol) were added to a solution of
7-hydroxy-6-methoxy-3,4-dihydroisoquinoline (80 mg, 0.45 mmol) and
3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol (83 mg, 0.3
mmol) in tetrahydrofuran (1 ml), followed by stirring at 50.degree.
C. for 3 hours. The reaction mixture was cooled to room temperature
and insoluble matters were removed by filtration. The filtrate was
concentrated under reduced pressure. The residue was purified by
basic silica gel column chromatography (n-hexane:ethyl
acetate=1:1), and concentrated under reduced pressure. The
resulting residue was dissolved in 2-propanol, and 1N-HCl--ethanol
solution was added thereto. Isopropyl ether was further added
thereto, then crystals precipitated were filtered out and dried to
obtain
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-6-methoxy-3,-
4-dihydroisoquinoline dihydrochloride (26 mg, yield: 17%) as light
yellow powder.
[0493] Melting point: 211.0-213.0.degree. C.
Example 58
Preparation of
1-acetyl-7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-te-
trahydroquinoline hydrochloride
[0494] Acetic anhydride (0.34 ml, 3.6 mmol) and pyridine (0.34 ml,
4.3 mmol) were added to a solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-tetrahydroq-
uinoline (0.49 g, 1.2 mmol) in methylene chloride (10 ml) with
cooling in an ice-bath, followed by stirring at room temperature
overnight. The reaction mixture was concentrated under reduced
pressure, and water and ethyl acetate were added to the residue to
separate the organic phase from the water phase. The organic phase
was washed with water, saturated sodium hydrogencarbonate aqueous
solution and brine in this order, and concentrated under reduced
pressure. The residue was purified by basic silica gel column
chromatography (n-hexane:ethyl acetate=1:1), and concentrated under
reduced pressure. The resulting residue was dissolved in ethyl
acetate (10 ml), and 1N-HCl--ethanol solution was added thereto.
Then, crystals precipitated were filtered out and dried to obtain
1-acetyl-7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-te-
trahydroquinoline hydrochloride (0.27 g, yield: 52%) as white
powder.
[0495] Melting point: 123.2-124.3.degree. C.
Example 59
Preparation of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-tetrahydroq-
uinoline hydrochloride
[0496] Lithium aluminum hydride (160 mg, 4.2 mmol) was added to a
solution of
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-q-
uinolin-2-one (1.6 g, 3.8 mmol) in tetrahydrofuran (40 ml),
followed by stirring under reflux for 1 hour. The reaction mixture
was cooled in an ice-bath, and water (0.16 ml), 15% sodium
hydroxide aqueous solution (0.16 ml) and water (0.5 ml) were added
thereto in this order. After stirring the mixture, insoluble
matters were removed by filtration and the filtrate was
concentrated under reduced pressure. The residue was purified by
basic silica gel column chromatography (n-hexane:ethyl
acetate=1:1), and concentrated under reduced pressure to obtain
amorphous solid (1.4 g). The amorphous solid obtained (0.6 g) was
dissolved in ethyl acetate (15 ml). 1N-HCl--ethanol solution (1.45
ml) was further added thereto, then crystals precipitated were
filtered out and dried to obtain
6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-tetr-
ahydroquinoline hydrochloride (0.55 g) as white powder.
[0497] Melting point: 123.2-124.3.degree. C.
Example 60
Preparation of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-1,2,3,4-te-
trahydroquinoline hydrochloride
[0498] 37% Formaldehyde aqueous solution (0.15 ml, 1.8 mmol),
MP-cyanoborohydride (2.41 mmol/g, 0.76 g, 1.8 mmol) and catalytic
amount of acetic acid were added to a solution of
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-tetrahydroi-
soquinoline (0.25 g, 0.6 mmol) in methanol (20 ml), followed by
stirring at room temperature overnight. The resin was removed by
filtration and the filtrate was concentrated under reduced
pressure. The residue was purified by basic silica gel column
chromatography (methylene chloride:methanol=20:1), and concentrated
under reduced pressure. The residue (175 mg) was dissolved in ethyl
acetate (5 ml). 1N-HCl--ethanol solution (0.42 ml) was further
added thereto, then crystals precipitated were filtered out and
dried to obtain
7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-1,2,3,4-te-
trahydroquinoline hydrochloride (103 mg, yield: 37%) as white
powder.
[0499] Melting point: 260.1-262.8.degree. C.
Example 61
Preparation of
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxyme-
thylamide dihydrochloride
[0500] Ethyl
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-quinolin-2-carboxyl-
ate (0.28 g) was added to a methanol solution of 40% methylamine
(10 ml), followed by stirring at room temperature for two days. The
reaction mixture was concentrated under reduced pressure. The
residue was purified by basic silica gel column chromatography
(ethyl acetate:methanol=11:1), and concentrated under reduced
pressure. The residue (166 mg) was dissolved in ethyl acetate.
1N-HCl--ethanol solution (0.7 ml) was further added thereto, then
crystals precipitated were filtered out and dried to obtain
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-ca-
rboxymethylamide dihydrochloride (0.17 g, yield: 54%) as white
powder.
[0501] Melting point: 224.0.degree. C. (decomposed)
Example 62
Preparation of
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxyli-
c acid hydrochloride
[0502] An aqueous solution of 4N lithium hydroxide (3 ml) was added
to a methanol solution (7 ml) of ethyl
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-quinolin-2-carboxyl-
ate (1.5 g), followed by stirring at room temperature overnight.
Then, water (10 ml) and aqueous solution (3 ml) of 4N lithium
hydroxide were further added, followed by stirring at 50.degree. C.
for 11 hours. The reaction mixture was cooled in an ice-bath, and
an aqueous solution (4 ml) of 6N-HCl was added thereto. Then,
crystals precipitated were filtered out, washed with water and
dried to obtain
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxyli-
c acid hydrochloride (1.43 g, yield: 98%) as white powder.
[0503] Melting point: 235.0.degree. C.
Example 63
Preparation of
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxami-
de
[0504] Triethylamine (0.25 ml, 1.8 mmol) and isobutyl chloroformate
(0.19 ml, 1.4 mmol) were added to a solution (10 ml) of
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxyli-
c acid (0.53 g, 1.2 mmol) in acetonitrile with cooling in an
ice-bath, followed by stirring at 0.degree. C. for 3 hours. 28%
Aqueous ammonia (0.15 ml) was added thereto and the reaction
mixture was stirred at room temperature for 5 minutes. Ethyl
acetate was further added thereto, then the reaction mixture was
washed with water and concentrated under reduced pressure. The
residue was purified by basic silica gel column chromatography
(n-hexane:ethyl acetate=3:1), and concentrated under reduced
pressure. The residue (0.2 g) was dissolved and recrystallized from
the mixed solvent of ethyl acetate and isopropyl ether to obtain
4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-quinolin-2-carboxam-
ide (79 mg, yield: 16%) as white powder.
[0505] Melting point: 153.0-154.5.degree. C.
Examples 64 to 196
[0506] Compounds of Example 64 to 196 shown in the following Tables
1 to 21 can be prepared in the same manner as in Example 1, using
corresponding starting materials. In the following Tables,
compounds with the physical properties, such as crystalline form,
m.p. (melting point), salt, .sup.1H-NMR and MS (mass spectrum),
were prepared actually.
TABLE-US-00001 TABLE 1 ##STR00023## crystalline form
(recrystallization Example No. R1 n solvent) m.p. (.degree. C.)
salt 64 ##STR00024## 3 white powder (methanol) 125-127 -- 65
##STR00025## 4 white powder (ethanol- ethyl acetate) 217-221
dihydrochloride 66 ##STR00026## 4 white powder (ethyl acetate)
123-130 (decomposed) --
TABLE-US-00002 TABLE 2 ##STR00027## crystalline form
(recrystallization Example No. R1 n solvent) m.p. (.degree. C.)
salt 67 ##STR00028## 3 white powder (ethanol) 253-255 (decomposed)
hydrochloride 68 ##STR00029## 4 white-powder (ethanol-ethyl
acetate- acetonitrile) 151-153 dihydrochloride 69 ##STR00030## 4
white powder (ethanol) 156-159 hydrochloride
TABLE-US-00003 TABLE 3 ##STR00031## crystalline form
(recrystallization Example No. R1 solvent) m.p. salt 70
##STR00032## colorless needle (ethanol) 106.0-108.0 -- 71
##STR00033## white powder (ethanol) 192.0-194.0 hydrochloride 72
##STR00034## light yellow powder (ethanol) 240-242 hydrochloride 73
##STR00035## light yellow powder (ethanol) 199.0-201.0
hydrochloride 74 ##STR00036## white powder (ethanol) 233.0-235.0
hydrochloride 75 ##STR00037## yellow powder 199.0-204.5
dihydrochloride 76 ##STR00038## white solid (ethyl acetate-hexane)
123.2-124.3 -- 77 ##STR00039## white solid (ethyl acetate)
231.3-232.9 hydrochloride 78 ##STR00040## white solid (ethyl
acetate) 229.6-231.3 hydrochloride 79 ##STR00041## white powder
(ethyl acetate) 237.0-238.5 hydrochloride 80 ##STR00042## white
solid (ethyl acetate) 214.5-216.8 hydrochloride
TABLE-US-00004 TABLE 4 ##STR00043## crystalline form
(recrystallization Example No. R1 solvent) m.p. salt 81
##STR00044## white solid (ethyl acetate) 207.9-208.7 hydrochloride
82 ##STR00045## light yellow powder (ethyl acetate-isopropyl ether)
106.0-113.0 -- 83 ##STR00046## white powder (ethyl acetate-ether)
188-190 --
TABLE-US-00005 TABLE 5 ##STR00047## Example No. R1 n 1H-NMR
(solvent) salt 84 ##STR00048## 3 1H-NMR (CDCl3) .delta. ppm:
2.05-2.20 (2H, m), 2.65-2.77 (6H, m), 3.15-3.25 (4H, m), 4.23 (2H,
t, J = 6.3 Hz), 6.91 (1H, d, J = 7.1 Hz), 7.15-7.35 (3H, m),
7.35-7.45 (3H, m), 7.55 (1H, d, J = 8.0 Hz), 7.70 (1H, d, J = 8.9
Hz), 8.05-8.15 (1H, m), 8.83 (1H, dd, J = 1.7, 5.3 Hz). -- 85
##STR00049## 4 1H-NMR (DMSO-d6) d: 1.90-2.00 (4H, m), 3.25-3.40
(6H, m), 3.50-3.65 (4H, m), 4.20-4.35 (2H m), 6.95 (1H, d, J = 7.4
Hz), 7.30 (1H, dd, J = 7.9, 7.9 Hz), 7.48 (1H, d, J = 5.5 Hz),
7.65-7.80 (3H, m), 7.80-7.95 (2H, m), 8.32 (1H, d, J = 9.2 Hz),
9.05-9.20 (2H, m), 11.29 (1H, brs). dihydrochloride
TABLE-US-00006 TABLE 6 ##STR00050## crystalline form
(recrystallization Example No. R1 solvent) m.p. (.degree. C.) salt
86 ##STR00051## white powder (ethyl acetate) 239.6-241.5
hydrochloride 87 ##STR00052## light brown powder (ethyl acetate)
228.3-229.5 hydrochloride 88 ##STR00053## white powder (ethyl
acetate) 212.3-214.4 hydrochloride 89 ##STR00054## white powder
(ethyl acetate) 232.9-235.1 hydrochloride 90 ##STR00055## white
powder (ethyl acetate) 165.8-167.9 hydrochloride 91 ##STR00056##
white powder (ethanol) 220-225 hydrochloride 92 ##STR00057## white
powder (ethanol) 221-224 hydrochloride 93 ##STR00058## white powder
(ethanol) 181-183 hydrochloride
TABLE-US-00007 TABLE 7 ##STR00059## Example No. R1 n 1H-NMR
(solvent) salt 94 ##STR00060## 3 1H-NMR (DMSO-d6) d: 2.01-2.12 (2H,
m), 3.0-3.7 (16H, m), 6.98 (1H, d, J = 7.7 Hz), 7.29-7.39 (3H, m),
7.47-7.52 (2H, m), 7.70 (1H, d, J = 8.0 Hz), 7.77 (1H, d, J = 5.6
Hz), 7.89 (1H, d, J = 7.7 Hz), 9.85 (1H, br-s) hydrochloride 95
##STR00061## 2 1H-NMR (CDCl3) d: 3.0-4.1 (16H, m), 6.94 (1H, d, J =
7.4 Hz), 7.20-7.47 (6H, m), 7.64 (1H, d, J = 8.1 Hz), 8.04 (1H, d,
J = 7.4 Hz) oxalate
TABLE-US-00008 TABLE 8 ##STR00062## crystalline form
(recrystallization Example No. R1 solvent) m.p.(.degree. C.) salt
96 ##STR00063## white powder (ethyl acetate) 185.5-190.0
hydrochloride 97 ##STR00064## white powder (ethyl acetate- ether)
134-136 -- 98 ##STR00065## white powder (ethyl acetate- ether)
103-105 -- 99 ##STR00066## white powder (ethyl acetate- ether)
126-128 -- 100 ##STR00067## white powder (ethyl acetate- ether)
97-99 -- 101 ##STR00068## brown powder (methanol) 240-242
hydrochloride 102 ##STR00069## white powder (ethyl acetate- ether)
143-145 -- 103 ##STR00070## white powder (ethyl acetate- ether)
161-163 -- 104 ##STR00071## white powder (ethyl acetate- ether)
122-124 --
TABLE-US-00009 TABLE 9 ##STR00072## crystalline form
(recrystallization Example No. R1 solvent) m.p.(.degree. C.) salt
105 ##STR00073## white powder (ethyl acetate) 212.5-216.0
hydrochloride 106 ##STR00074## white powder (ethyl acetate)
224.5-230.0 hydrochloride 107 ##STR00075## white powder (ethyl
acetate) 172.0-174.5 hydrochloride 108 ##STR00076## white powder
(ethyl acetate) 196.5-201.5 hydrochloride 109 ##STR00077## white
powder (ethyl acetate) 200.5-205.5 hydrochloride 110 ##STR00078##
white powder (ethyl acetate) 202.5-206.5 hydrochloride 111
##STR00079## white powder (ethyl acetate) 218.0-223.5 hydrochloride
112 ##STR00080## white powder (ethyl acetate- isopropyl ether)
125.0-129.0 --
TABLE-US-00010 TABLE 10 ##STR00081## Example No. R1 n MS(M + 1) 113
##STR00082## 3 454 114 ##STR00083## 3 501 115 ##STR00084## 3 448
116 ##STR00085## 3 440 117 ##STR00086## 3 434 118 ##STR00087## 3
438 119 ##STR00088## 3 502 120 ##STR00089## 3 457 121 ##STR00090##
3 420
TABLE-US-00011 TABLE 11 ##STR00091## Example No. R1 n MS(M + 1) 122
##STR00092## 3 422 123 ##STR00093## 3 422 124 ##STR00094## 3 499
125 ##STR00095## 3 535 126 ##STR00096## 3 457 127 ##STR00097## 3
478 128 ##STR00098## 3 480 129 ##STR00099## 3
TABLE-US-00012 TABLE 12 ##STR00100## Example No. R1 n MS(M + 1) 130
##STR00101## 3 499 131 ##STR00102## 3 434 132 ##STR00103## 3 133
##STR00104## 3 434 134 ##STR00105## 3 528 135 ##STR00106## 3 465
136 ##STR00107## 3 450 137 ##STR00108## 3 482
TABLE-US-00013 TABLE 13 ##STR00109## Example No. R1 n MS(M + 1) 138
##STR00110## 3 139 ##STR00111## 3 452 140 ##STR00112## 3 448 141
##STR00113## 3 496 142 ##STR00114## 3 143 ##STR00115## 3 462 144
##STR00116## 3 491 145 ##STR00117## 3
TABLE-US-00014 TABLE 14 ##STR00118## Example No. R1 n MS(M + 1) 146
##STR00119## 3 498 147 ##STR00120## 3 148 ##STR00121## 3 464 149
##STR00122## 3 501 150 ##STR00123## 3 480 151 ##STR00124## 3 462
152 ##STR00125## 3 467 153 ##STR00126## 3 467 154 ##STR00127## 3
452
TABLE-US-00015 TABLE 15 ##STR00128## Example No. R1 n MS(M + 1) 155
##STR00129## 3 479 156 ##STR00130## 3 157 ##STR00131## 3 436 158
##STR00132## 3 467 159 ##STR00133## 3 525 160 ##STR00134## 3 161
##STR00135## 3 162 ##STR00136## 3 491
TABLE-US-00016 TABLE 16 ##STR00137## Example No. R1 n MS(M + 1) 163
##STR00138## 3 491 164 ##STR00139## 3 494 165 ##STR00140## 3 166
##STR00141## 3 167 ##STR00142## 3 168 ##STR00143## 3 479 169
##STR00144## 3 519 170 ##STR00145## 3
TABLE-US-00017 TABLE 17 ##STR00146## Example No. R1 n MS(M + 1) 171
##STR00147## 3 479 172 ##STR00148## 3 448 173 ##STR00149## 2 408
174 ##STR00150## 2 175 ##STR00151## 2 406 176 ##STR00152## 2 442
177 ##STR00153## 2 408 178 ##STR00154## 2 408 179 ##STR00155## 5
450 180 ##STR00156## 8 518
TABLE-US-00018 TABLE 18 ##STR00157## Example No. R1 n MS(M + 1) 181
##STR00158## 4 471 182 ##STR00159## 4 183 ##STR00160## 4 469 184
##STR00161## 4 452 185 ##STR00162## 4 448 186 ##STR00163## 4 436
187 ##STR00164## 4 436 188 ##STR00165## 4 434 189 ##STR00166## 4
450 190 ##STR00167## 3 438
TABLE-US-00019 TABLE 19 ##STR00168## Example No. R1 MS(M + 1) 191
##STR00169## 438 192 ##STR00170## 438 193 ##STR00171## 436
TABLE-US-00020 TABLE 20 ##STR00172## Example No. R1 MS(M + 1) 194
##STR00173## 436 195 ##STR00174## 436 196 ##STR00175## 434
TABLE-US-00021 TABLE 21 ##STR00176## Example No. R1 MS(M + 1) 197
##STR00177##
Pharmacological Test 1
1) Dopamine D.sub.2 Receptor Binding Assay
[0507] The assay was performed according to the method by Kohler et
al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro
and in vivo binding of 3H-raclopride. A potent substituted
benzamide drug with high affinity for dopamine D-2 receptors in the
rat brain. Biochem. Pharmacol., 1985; 34: 2251-2259).
[0508] Wistar male rats were decapitated, the brain was retrieved
immediately and corpus striatum was taken out. It was homogenized
in 50 mM tris(hydroxymethyl)aminomethane (Tris)-hydrochloric acid
buffer (pH 7.4) of a volume 50 times of the weight of the tissue
using a homogenizer with a high-speed rotating blade, and
centrifuged at 4.degree. C., 48,000.times.g for 10 minutes. The
obtained precipitate was suspended again in the above-described
buffer of a volume 50 times of the weight of the tissue and after
incubated at 37.degree. C. for 10 minutes, centrifuged in the
above-described condition. The obtained precipitate was suspended
in 50 mM (Tris)-hydrochloric acid buffer (containing 120 mM NaCl, 5
mM KCl, 2 mM CaCl.sub.2, 1 mM MgCl.sub.2, pH 7.4) of a volume 25
times of the weight of the tissue and preserved by freezing at
-85.degree. C. till it was used for binding assay as a membrane
specimen.
[0509] The binding assay was performed using 40 .mu.l of the
membrane specimen, 20 .mu.l of [.sup.3H]-raclopride (final
concentration 1 to 2 nM), 20 .mu.l of a test drug and 50 mM
Tris-hydrochloric acid buffer (containing 120 mM NaCl, 5 mM KCl, 2
mM CaCl.sub.2, 1 mM MgCl.sub.2, pH 7.4) so that the total amount
was 200 .mu.l (final dimethylsulfoxide concentration 1%). The
reaction was performed at room temperature for 1 hour and
terminated by conducting suction filtration with a cell harvester
on a glass fiber filter plate. The filter plate made of glass fiber
was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and
after dried, a microplate liquid scintillation cocktail was added
and the radioactivity was measured with a microplate scintillation
counter. Radioactivity in the presence of 10 .mu.M (+)-butaclamol
hydrochloride was assumed as nonspecific binding.
[0510] IC.sub.50 value was calculated from concentration-dependent
reaction using a non-linear analysis program. Ki value was
calculated from IC.sub.50 value using Cheng-Prussoff formula. The
results are shown in the following Table 22.
TABLE-US-00022 TABLE 22 Test Compound Ki (nM) Compound of Example 1
0.2 Compound of Example 3 0.5 Compound of Example 4 0.5 Compound of
Example 5 0.6 Compound of Example 6 0.8 Compound of Example 7 0.5
Compound of Example 10 0.4 Compound of Example 11 0.1 Compound of
Example 12 0.1 Compound of Example 13 2.4 Compound of Example 14
3.2 Compound of Example 15 0.2 Compound of Example 16 0.7 Compound
of Example 17 2.2 Compound of Example 18 2.6 Compound of Example 19
1.2 Compound of Example 20 1.5 Compound of Example 22 4.0 Compound
of Example 23 0.7 Compound of Example 24 5.0 Compound of Example 26
3.5 Compound of Example 27 4.9 Compound of Example 28 1.2 Compound
of Example 30 0.7 Compound of Example 31 1.4 Compound of Example 32
1.5 Compound of Example 33 1.1 Compound of Example 34 1.2 Compound
of Example 35 1.6 Compound of Example 36 1.0 Compound of Example 37
1.9 Compound of Example 38 1.2 Compound of Example 39 1.2 Compound
of Example 40 4.8 Compound of Example 41 1.9 Compound of Example 64
3.2 Compound of Example 68 1.0 Compound of Example 69 0.8 Compound
of Example 73 4.0 Compound of Example 79 4.7 Compound of Example 80
1.5 Compound of Example 81 0.8 Compound of Example 84 2.4 Compound
of Example 85 2.0 Compound of Example 90 0.4 Compound of Example 91
1.4 Compound of Example 92 1.7 Compound of Example 116 4.5 Compound
of Example 117 4.7 Compound of Example 118 3.5 Compound of Example
122 3.3 Compound of Example 128 1.3 Compound of Example 139 0.2
Compound of Example 155 2.3 Compound of Example 163 2.8 Compound of
Example 184 2.6 Compound of Example 185 2.7 Compound of Example 186
2.3 Compound of Example 188 1.6 Compound of Example 190 0.8
2) Serotonin 5-HT.sub.2A Receptor Binding Assay
[0511] The assay was performed according to the method by Leysen J
E et al. (Leysen J E, Niemegeers C J E, Van Nueten J M and Laduron
P M. [3H] Ketanserin (R 41 468), a selective 3H-ligand for
serotonin 2 receptor binding sites. Mol. Pharmacol., 1982, 21:
301-314).
[0512] Wistar male rats were decapitated, the brain was retrieved
immediately and frontal cortex was taken out. It was homogenized in
0.25 M sucrose of a volume 10 times of the weight of the tissue
using a Teflon glass homogenizer, and centrifuged at 4.degree. C.,
1,000.times.g for 10 minutes. The obtained supernatant was
transferred to another centrifuge tube and suspended in 0.25 M
sucrose of a volume 5 times of the weight of the tissue and the
precipitate was centrifuged in the above-described condition. The
obtained supernatant was combined with the supernatant obtained
above and adjusted to a volume 40 times of the weight of the tissue
with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and centrifuged
at 4.degree. C., 35,000.times.g for 10 minutes. The obtained
precipitate was suspended again in the above-described buffer of a
volume 40 times of the weight of the tissue and centrifuged in the
above-described condition. The obtained precipitate was suspended
in the above-described buffer of a volume 20 times of the weight of
the tissue and preserved by freezing at -85.degree. C. till it was
used for binding assay as a membrane specimen.
[0513] The binding assay was performed using 40 .mu.l of the
membrane specimen, 20 .mu.l of [.sup.3H]-Ketanserin (final
concentration 1 to 3 nM), 20 .mu.l of a test drug and 50 mM
Tris-hydrochloric acid buffer (pH 7.4) so that the total amount was
200 .mu.l (final dimethylsulfoxide concentration 1%). The reaction
was performed at 37.degree. C. for 20 minutes and terminated by
conducting suction filtration with a cell harvester on a glass
fiber filter plate.
[0514] The filter plate made of glass fiber was washed with 50 mM
Tris-hydrochloric acid buffer (pH 7.4), and after dried, a
microplate liquid scintillation cocktail was added and the
radioactivity was measured with a microplate scintillation counter.
Radioactivity in the presence of 10 .mu.M spiperone was assumed as
nonspecific binding.
[0515] IC.sub.50 value was calculated from concentration-dependent
reaction using a non-linear analysis program. Ki value was
calculated from IC.sub.50 value using Cheng-Prussoff formula. The
results are shown in the following Table 23.
TABLE-US-00023 TABLE 23 Test Compound Ki (nM) Compound of Example 1
2.3 Compound of Example 2 1.5 Compound of Example 3 2.3 Compound of
Example 4 4.9 Compound of Example 5 6.4 Compound of Example 7 4.0
Compound of Example 8 0.6 Compound of Example 9 2.6 Compound of
Example 10 3.0 Compound of Example 11 5.7 Compound of Example 12
2.1 Compound of Example 15 3.3 Compound of Example 16 7.0 Compound
of Example 17 2.8 Compound of Example 18 8.0 Compound of Example 19
1.2 Compound of Example 20 3.3 Compound of Example 21 1.0 Compound
of Example 22 2.9 Compound of Example 23 1.7 Compound of Example 24
2.3 Compound of Example 25 4.6 Compound of Example 26 4.4 Compound
of Example 27 4.1 Compound of Example 28 2.8 Compound of Example 30
2.0 Compound of Example 31 4.5 Compound of Example 32 8.6 Compound
of Example 33 6.6 Compound of Example 34 1.5 Compound of Example 35
2.1 Compound of Example 36 2.1 Compound of Example 37 3.1 Compound
of Example 38 7.3 Compound of Example 39 2.1 Compound of Example 40
5.1 Compound of Example 41 3.2 Compound of Example 64 8.2 Compound
of Example 68 7.0 Compound of Example 69 6.1 Compound of Example 73
1.3 Compound of Example 79 5.5 Compound of Example 80 2.5 Compound
of Example 81 2.6 Compound of Example 84 3.3 Compound of Example 89
3.1 Compound of Example 90 5.3 Compound of Example 91 6.5 Compound
of Example 92 5.7 Compound of Example 116 4.2 Compound of Example
117 1.3 Compound of Example 118 3.4 Compound of Example 122 2.9
Compound of Example 128 6.3 Compound of Example 139 4.0 Compound of
Example 155 3.0 Compound of Example 163 7.4 Compound of Example 184
4.3 Compound of Example 185 5.0 Compound of Example 186 8.8
Compound of Example 188 6.3 Compound of Example 190 2.9
3) Adrenalin .alpha.1 Receptor Binding Assay
[0516] The assay was performed according to the method by Gro.beta.
G et al. (Gro.beta. G, Hanft G and Kolassa N. Urapidil and some
analogues with hypotensive properties show high affinities for
5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and
for .alpha.1-adrenoceptor binding sites. Naunyn-Schmiedeberg's Arch
Pharmacol., 1987, 336: 597-601).
[0517] Wistar male rats were decapitated, the brain was retrieved
immediately and cerebral cortex was taken out. It was homogenized
in 50 mM Tris-hydrochloric acid buffer (100 mM NaCl, containing 2
mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a
volume 20 times of the weight of the tissue using a homogenizer
with a high-speed rotating blade, and centrifuged at 4.degree. C.,
80,000.times.g for 20 minutes. The obtained precipitate was
suspended in the above-described buffer of a volume 20 times of the
weight of the tissue and after incubated at 37.degree. C. for 10
minutes, centrifuged in the above-described condition. The obtained
precipitate was suspended again in the above-described buffer of a
volume 20 times of the weight of the tissue and centrifuged in the
above-described condition. The obtained precipitate was suspended
in 50 mM (Tris)-hydrochloric acid buffer (containing 1 mM
dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a
volume 20 times of the weight of the tissue and preserved by
freezing at -85.degree. C. till it was used for binding assay as a
membrane specimen.
[0518] The binding assay was performed using 40 .mu.l of the
membrane specimen, 20 .mu.l of [.sup.3H]-prazosin (final
concentration 0.2 to 0.5 nM), 20 .mu.l of a test drug and 50 mM
Tris-hydrochloric acid buffer (containing 1 mM EDTA, pH 7.4) so
that the total amount was 200 .mu.l (final dimethylsulfoxide
concentration 1%). The reaction was performed at 30.degree. C. for
45 minutes and terminated by conducting suction filtration with a
cell harvester on a glass fiber filter plate.
[0519] The filter plate made of glass fiber was washed with 50 mM
Tris-hydrochloric acid buffer (pH 7.4), and after dried, a
microplate liquid scintillation cocktail was added and the
radioactivity was measured with a microplate scintillation counter.
Radioactivity in the presence of 10 .mu.M phentolamine
hydrochloride was assumed as nonspecific binding.
[0520] IC.sub.50 value was calculated from concentration-dependent
reaction using a non-linear analysis program. Ki value was
calculated from IC.sub.50 value using Cheng-Prussoff formula.
Pharmacological Test 2
[0521] Partial Agonistic Activity on Dopamine D.sub.2 Receptor
Using D.sub.2 Receptor Expression Cells
[0522] Partial agonistic activity on dopamine D.sub.2 receptor was
evaluated by quantitatively determining cyclic AMP production
inhibitory effect of a test compound in dopamine D.sub.2 receptor
expression cells in which adenosine 3',5'-cyclic monophosphate
(cyclic AMP) production was induced by forskolin stimulation.
[0523] Human recombinant dopamine D.sub.2 receptor expressing
Chinese hamster ovary/DHFR(-) cells were cultured in a culture
medium (Iscove's Modified Dulbecco's Medium (IMDM culture medium),
10% fetal bovine serum, 50 I.U./ml penicillin, 50 .mu.g/ml
streptomycin, 200 .mu.g/ml geneticin, 0.1 mM sodium hypoxanthine,
16 .mu.M thymidine) at 37.degree. C. and 5% carbon dioxide
condition. Cells were seeded at 10.sup.4 cells/well on a 96-well
microtiter plate coated with poly-L-lysine and grown under the same
condition for 2 days. Each well was washed with 100 .mu.l of a
culture medium (IMDM culture medium, 0.1 mM sodium hypoxanthine, 16
.mu.M thymidine). The culture medium was replaced with 50 .mu.l of
culture medium (IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM
sodium hypoxanthine, 16 .mu.M thymidine) having dissolved therein 3
.mu.M of a test compound. After allowed to incubate at 37.degree.
C., 5% carbon dioxide condition for 20 minutes, the culture medium
was replaced with 100 .mu.l of forskolin stimulative culture medium
(IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium
hypoxanthine, 16 .mu.M thymidine, 10 .mu.M forskolin, 500 .mu.M
3-isobutyl-1-methylxanthine) having 3 .mu.M of the test compound
dissolved therein and allowed to incubate at 37.degree. C., 5%
carbon dioxide condition for 10 minutes. After the culture medium
was removed, 200 .mu.l of Lysis 1B aqueous solution (Amersham
Bioscience, reagent attached to cyclic AMP biotrack enzyme
immunoassay system) was dispensed and shaken for 10 minutes. The
aqueous solution of each well was used as a sample for measurement.
Samples for measurement quadruply diluted were subjected to
measurement of the quantity of cyclic AMP using the above-described
enzyme immunoassay system. Inhibition ratio of the respective test
compound was calculated assuming that the quantity of cyclic AMP of
the well to which no test compound was added was 100%. In this
empiric test system, dopamine which was used as a control drug
suppressed the quantity of cyclic AMP to about 10% as the maximum
activity.
[0524] It was confirmed that test compounds had partial agonistic
activity for dopamine D.sub.2 receptor in the above-described
test.
[0525] Since the test compounds has partial agonistic activity for
dopamine D.sub.2 receptor, they can stabilize dopamine
neurotransmission to a normal condition in a schizophrenia patient
and as a result, exhibit, for example, positive and negative
condition improving effect, cognitive impairment improving effect
and the other symptom improving effects without causing side
effects.
Pharmacological Test 3
[0526] Inhibitory Effect on Apomorphine-Induced Stereotyped
Behavior in Rats
[0527] Wistar rats (male, six-seven weeks old, Japan SLC, Inc.)
were used as test animals. A test compound was suspended in 5% gum
arabic/(physiological saline or water) using an agate mortar and
was diluted with the same solvent if necessary.
[0528] Test animals were fasted overnight from the day before.
Apomorphine (0.7 mg/kg) was subcutaneously administered (1 ml/kg) 1
hour after each test compound was orally administered (5 ml/kg).
Stereotyped behavior was observed for 1 minute respectively 20, 30
and 40 minutes after apomorphine injection.
[0529] The stereotyped behavior of each animal was quantified
according to the following condition and score made at three points
were summed up and the anti-apomorphine effect was evaluated. Six
test animals were used for each group.
[0530] 0: The appearance of the animals is the same as saline
treated rats;
[0531] 1: Discontinuous sniffing, constant exploratory
activity;
[0532] 2: Continuous sniffing, periodic exploratory activity;
[0533] 3: Continuous sniffing, discontinuous biting, gnawing or
licking. Very brief periods of locomotor activity;
[0534] 4: Continuous biting, gnawing or licking; no exploratory
activity.
[0535] Non-clinical statistical analysis system was used for all
statistical processing. When the significance probability value was
lower than 0.05, it was judged that a significant difference
existed. The difference of the score between the solvent
administration group and each test compound administration group
was analyzed using Wilcoxon rank-sum test or Steel test. In
addition, linear regression analysis was used for calculating 50%
effective dose (95% confidence interval).
[0536] Since the test compounds showed inhibitory effect for
apomorphine-induced stereotyped behavior, it was confirmed that the
test compounds have D.sub.2 receptor antagonistic effect.
Pharmacological Test 4
[0537] Inhibitory Effect on (.+-.)D-2,5-dimethoxy-4-Iodoamphetamine
(DOI) Induced Head Twitch in Rats
[0538] Wistar rats (male, six-seven weeks old, Japan SLC, Inc.)
were used as test animals. A test compound was suspended in 5% gum
arabic/(physiological saline or water) using an agate mortar and
was diluted with the same solvent if necessary.
[0539] Test animals were fasted overnight from the day before. DOI
(5.0 mg/kg) was subcutaneously administered (1 ml/kg) 1 hour after
each test compound was orally administered (5 ml/kg). The number of
head twitches was counted for 10 minutes immediately after DOI
injection. Six test animals were used for each group.
[0540] Non-clinical statistical analysis was used for all
statistical processing. When the significance probability value was
lower than 0.05, it was judged that a significant difference
existed. The difference of the number of head twitches between the
solvent administration group and each test compound administration
group was analyzed using t-test or Dunnett's test. In addition,
linear regression analysis was used for calculating 50% effective
dose (95% confidence interval).
[0541] Since the test compounds showed inhibitory effect for
DOI-induced head twitch, it was confirmed that the test compounds
have serotonin 5HT.sub.2A receptor antagonistic effect.
Pharmacological Test 5
[0542] Catalepsy Inducing Effect in Rats
[0543] Wistar rats (male, six-seven weeks old, Japan SLC, Inc.)
were used as test animals. A test compound was suspended in 5% gum
arabic/(physiological saline or water) using an agate mortar and
was diluted with the same solvent if necessary.
[0544] Test animals were fasted overnight from the day before
observation on catalepsy and ptosis was performed 1, 2, 4, 6 and 8
hours after each test compound was orally administered (5 ml/kg).
Six test animals were used for each group.
[0545] One forepaw of a rat was placed on an edge of a steel small
box (width: 6.5 cm, depth: 4.0 cm, height: 7.2 cm) (an unnatural
pose) and when the rat maintained the pose for more than 30
seconds, it was judged that the case was catalepsy positive. This
observation was performed three times at each point, and if there
was at least one positive case, it was judged that catalepsy
occurred in the individual.
[0546] As a result, catalepsy induction effect of a test compound
was dissociated from inhibitory effect on apomorphine-induced
stereotyped behavior, therefore it was suggested that apprehension
for extrapyramidal side effect in clinic would be low.
Pharmacological Test 6
[0547] Measurement of Serotonin (5-HT) Uptake Inhibitory Activity
of a Test Compound by Rat Brain Synaptosome
[0548] Wistar male rats were decapitated, the brain was retrieved
and frontal cortex was dissected out, and it was homogenized in
0.32 M sucrose solution of a weight 20 times of the weight of the
tissue using a Potter type homogenizer. The homogenate was
centrifuged at 4.degree. C., 1,000.times.g for 10 minutes, the
obtained supernatant was further centrifuged at 4.degree. C.,
20,000.times.g for 20 minutes, and the pellet was suspended in an
incubation buffer (20 mM Hepes buffer (pH 7.4) containing 10 mM
glucose, 145 mM sodium chloride, 4.5 mM potassium chloride, 1.2 mM
magnesium chloride, 1.5 mM calcium chloride), which was used as
crude synaptosome fraction.
[0549] 5-HT uptake reaction was performed in a volume of 200 .mu.l
using a 96-well round bottom plate and pargyline (final
concentration 10 .mu.M) and sodium ascorbate (final concentration
0.2 mg/ml) were contained in the incubation buffer upon reaction
and used.
[0550] Incubation buffer (total counting), non-labeled 5-HT (final
concentration 10 .mu.M, non-specific counting) and the diluted test
compound (final concentration 300 nM) were added to each well.
One-tenth quantity of the final volume of the synaptosome fraction
was added and after preincubated at 37.degree. C. for 10 minutes,
tritium labeled 5-HT solution (final concentration 8 nM) was added
and uptake reaction was started at 37.degree. C. The uptake time
was 10 minutes and the reaction was terminated by vacuum filtration
through a 96-well fiber glass filter paper plate, and after the
filter paper was washed with cold normal saline, it was dried
enough and Microscint0 (Perkin-Elmer) was added to the filter and
remaining radioactivity on the filter was measured.
[0551] Serotonin uptake inhibitory activity (%) was calculated from
the radioactivity of total counting as 100%, of non-specific
counting as 0%, and of counting obtained with test compound.
% of inhibition of 5-HT(%)=100-[(Count obtained with test
compound-Nonspecific count(0% Uptake))/(Total count(100%
Uptake)-Nonspecific count(0% Uptake))].times.100
[0552] The results are shown in the next Table 24.
TABLE-US-00024 TABLE 24 Serotonin uptake inhibitory Test compound
ratio (%)(300 nM) Compound of Example 1 92.4 Compound of Example 2
78.8 Compound of Example 3 84.8 Compound of Example 4 91.0 Compound
of Example 5 89.1 Compound of Example 6 91.3 Compound of Example 7
91.0 Compound of Example 8 95.0 Compound of Example 9 97.3 Compound
of Example 10 92.6 Compound of Example 11 92.5 Compound of Example
13 77.0 Compound of Example 14 85.2 Compound of Example 15 87.2
Compound of Example 16 86.7 Compound of Example 17 86.3 Compound of
Example 18 91.1 Compound of Example 19 86.3 Compound of Example 20
92.8 Compound of Example 21 81.4 Compound of Example 22 90.8
Compound of Example 23 95.5 Compound of Example 24 97.5 Compound of
Example 25 91.9 Compound of Example 26 92.0 Compound of Example 27
94.0 Compound of Example 28 95.3 Compound of Example 30 95.8
Compound of Example 31 96.3 Compound of Example 32 96.9 Compound of
Example 33 94.3 Compound of Example 34 94.2 Compound of Example 35
93.4 Compound of Example 36 97.4 Compound of Example 37 97.7
Compound of Example 38 96.7 Compound of Example 39 99.2 Compound of
Example 40 91.6 Compound of Example 41 95.1 Compound of Example 64
73.0 Compound of Example 65 72.9 Compound of Example 66 74.1
Compound of Example 67 93.9 Compound of Example 68 95.7 Compound of
Example 69 96.3
Preparation Examples
[0553] 100 g of a compound of the present invention, 40 g of Avicel
(trade name, product of Asahi Chemical Industry Co., Ltd.), 30 g of
corn starch and 2 g of magnesium stearate was mixed and polished
and tableted with a pestle for glycocalyx R10 mm.
[0554] The obtained tablet was coated with a film using a film
coating agent made up of 10 g of TC-5 (trade name, product of
Shin-Etsu Chemical Co., Ltd., hydroxypropyl methylcellulose), 3 g
of polyethylene glycol 6000, 40 g of castor oil and an appropriate
amount of ethanol to produce a film coated tablet of the above
composition.
* * * * *